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Preface 
Development of novel synthetic methodologies towards heterocyclic 
molecules is of exceptional importance in a view of their potential ap-
plications in medicinal chemistry. A recent success in the use of multi-
component reaction as well as a fast rise of a diversity-oriented syn-
thesis (DOS) concept prompted us to start work in this direction. 
Our group has a long-standing interest in the Ugi reaction chemistry 
and in the triple bond functionalizations. Getting inspiration from there, 
we decided to put an emphasis on the application of 3-substituted 
propiolic acids in a four-component Ugi reaction anticipating that the 
triple bond of propiolic acid in combination with other functionalities 
would allow to subject the resulting Ugi adducts to a large variety of 
post-transformations. This resulted in the development of several 
practical methodologies providing a diversity-oriented access towards 
a number of interesting heterocyclic scaffolds such as pyrrolones, ox-
azepines and 3-benzazepines. 
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Summary 
The research described in this thesis centers on the application of 3-
substituted propiolic acids in a four-component Ugi reaction. The tri-
ple bond of propiolic acid in combination with other functionalities 
produces an important type of Ugi adducts which could be then readi-
ly applied in a large variety of post-transformations providing a diver-
sity-oriented access towards a large number of heterocyclic scaffolds 
(Scheme 1).  
 
Scheme 1. General concept  
Chapter 1 serves as an introduction into the post-Ugi chemistry in 
general, and into the reactivity of Ugi-adducts bearing C-C triple bond 
in particular. The objectives and targets of the current research are 
also formulated in this chapter. 
Chapter 2 is dedicated to the elaboration of a novel cascade trans-
formation involving Ugi reaction followed by enolization-triggered 5-
endo-dig carbocyclization and retro-Claisen fragmentation providing 
an efficient and fast access to 1H-pyrrol-2(5H)-one core. 
 x 
Chapter 3 describes a comprehensive study on gold- and silver-
catalyzed cycloisomerizations of hydroxypropargylamides into oxaze-
pines. Three different types of hydroxypropargylamide substrates de-
rived from either amide coupling or Ugi reaction have been validated 
providing selective and general access to a medium-ring oxazepine 
core. 
Chapter 4 deals with a two-step sequence involving Ugi reaction fol-
lowed by reductive Heck cyclization leading to a 3-benzazepine 
framework. Several aspects related to the substrate scope and the 
optimal distribution of the required functional groups have been ad-
dressed, resulting in a diversity-oriented synthesis of a small library of 
title compounds, featuring four distinct types of substitution pattern. 
Finally, General conclusions and future perspectives are outlined. 
 xi 
Samenvatting 
Het onderzoek dat in deze thesis beschreven wordt, handelt over de 
toepassing van 3-gesubstitueerde propiolzuren in een vier-component 
Ugi reactie. De drievoudige binding van dit propiolzuur, in combinatie 
met andere functionaliteiten, resulteert in de vorming van een 
belangrijk type van Ugi-adduct dat kan gebruikt worden in een grote 
variëteit van op diversiteit-georiënteerde post-transformaties, die 
toegang geven tot een groot aantal heterocyclische skeletten 
(Schema 1). 
 
Schema 1. Algemeen concept.  
Hoofdstuk 1:  
Inleiding tot post-Ugi transformaties in het algemeen, en tot de 
reactiviteit van Ugi-adducten, welke een C-C drievoudige dragen, in 
het bijzonder. De specifieke doelen en objectieven van dit onderzoek 
 xii 
worden eveneens geformuleerd en bekommentarieerd in dit 
hoofdstuk. 
Hoofdstuk 2:  
Op punt stellen van een nieuwe cascadereactie waarbij een Ugi-
reactie betrokken is, gevolgd door een enolisatie-gestuurde 5-endo-
dig carbocyclisatie en retro-Claisen-fragmentatie, resulterend in de 
efficiënte en snelle vorming van het 1H-pyrrol-2(5H)-on-skelet.  
Hoofdstuk 3: 
Studie van goud- en zilver-gekatalyseerde cycloïsomerisaties van 
hydroxypropargylamides leidend tot oxazepines. Drie verschillende 
types van hydroxypropargylamidesubstraten – gesynthetiseerd via 
amidekoppeling of via Ugi-reactie - worden onderzocht voor de 
selectieve synthese van oxazepines van medium ringgrootte.  
Hoofdstuk 4: 
Twee-stapsreactie van een Ugi-reactie gevolgd door een reductieve 
Heck-cyclisatie, met vorming van een 3-benzazepineskelet. 
Verschillende aspecten betrekking hebbende op de variatie van het 
substraat en de optimale verdeling van de vereiste functionele 
groepen worden onderzocht, resulterend in een op diversiteit 
geöriënteerde synthese van een kleine bibliotheek van deze 
verbindingen, die vier verschillende types van substitutiepatroon 
vertonen. 
Finaal besluit en toekomstperspectieven.  
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Chapter 1 
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1. Introduction and objectives of the work 
1.1. The Ugi reaction for the synthesis of heterocycles 
Multicomponent reactions (MCRs) constitute one of the most powerful 
and attractive tools in synthetic organic chemistry allowing the gener-
ation of structurally complex and diverse products in a step- and at-
om-economic manner from rather simple and accessible precursors.1 
Since the first report by Ivar Ugi and co-workers,2 the four-component 
Ugi reaction has been considered as one of the most versatile and 
robust MCRs.3 The typical Ugi reaction utilizes a carboxylic acid 1, an 
aldehyde (more rarely ketone) 2, a primary amine 3 and an isocya-
nide 4. The Ugi reaction is believed to start with a condensation of an 
aldehyde 2 and an amine 3 to form an imine A with a concomitant 
loss of one equivalent of water. Protonation by a carboxylic acid 1 
leads to the formation of an activated iminium ion B that undergoes 
nucleophilic attack by an isocyanide 4. The resulting intermediate D 
undergoes second nucleophilic addition with the carboxylic acid anion 
C to form E. The final step is a Mumm rearrangement4 that transfers 
the R1 acyl group from oxygen to amine-originated nitrogen to afford a 
final linear product 5 featuring a peptide backbone (Scheme 2). 
 4 
 
Scheme 2. The typical four-component Ugi reaction. 
The possibilities to rigidify the Ugi adduct do exist. Thus, a considera-
ble part of Ugi-based synthetic protocols, either directly or in combina-
tion with various post-transformations, aim for the diversity-oriented 
synthesis of heterocyclic scaffolds. The easiest way is to get the het-
erocyclic core directly via Ugi reaction by combining two of the re-
quired functionalities in one of the components. This approach is illus-
trated by a four-center three-component Ugi reaction elaborated by 
Fülöp and coworkers that utilizes alicyclic β-amino acids 6, aldehydes 
2, and isocyanides 4 to obtain alicyclic β-lactams 7 (Scheme 3).5 
 
 5 
 
Scheme 3. Three-component Ugi reaction for the synthesis of alicy-
clic β-lactams 7. 
A similar idea was exploited by Tye and Whittaker in the microwave-
assisted three-component Ugi reaction of levulinic acid 8 with various 
amines 3, and isocyanides 4 for the preparation of γ-lactam deriva-
tives 9 (Scheme 4).6  
 
Scheme 4. Three-component Ugi reaction for the synthesis of γ-
lactams 9. 
The carbonyl and acidic functionalities could also be linked through 
the biaryl moiety. The application of such substrates 10 and 12 in the 
Ugi reaction provided an efficient access to biologically relevant librar-
ies of indolobenzazepinones 11 (Scheme 5a)7 and dibenzoaze-
pinones 13 (Scheme 5b).8 
 6 
 
Scheme 5. Synthesis of seven-membered azepine frameworks 11 
and 13 via three-component Ugi reaction. 
As can be seen from the above examples the direct strategy could be 
useful to access various types of heterocycles when combined with 
some basic elements of rational design. However, it still suffers from 
one major drawback, which is the limited number of possibilities that 
allow incorporating two Ugi-functionalities in one substrate. Thus, a 
more common way to attain heterocycles through the Ugi chemistry 
would be to use different post-transformations.9,10 This is possible 
when the Ugi reaction is conducted with starting materials that bear 
one or two additional functional groups. The resulting Ugi-adducts 14 
and 17 could be then subjected to further transformations, typically 
cyclizations, eventually yielding heterocyclic cores 15, 16 and 18 
(Scheme 6).  
 7 
 
Scheme 6. Post- Ugi transformations leading to heterocycles. 
Furthermore, the power of the Ugi/post-transformation sequence 
could be reinforced when the same Ugi-adduct is converted into sev-
eral different heterocyclic scaffolds. In 2013, Liu and co-workers de-
scribed a rapid and selective access to three distinct sets of indole-
based heterocycles 22-24 from a single set of Ugi-adducts 21 derived 
from 2-iodobenzoic acid 19 and indole-2-carbaldehyde 20 (Scheme 
7).11 When adducts 21 were subjected to copper catalysis in the 
presence of L-proline and K2CO3, N1-indole-arylation products 22 
were preferentially formed. Remarkably, switching to palladium catal-
ysis drove the reaction in the direction of C3-indole-arylation selec-
 8 
tively yielding product 23. Finally, isoindolinone derivatives 24 were 
efficiently assembled through Cs2CO3-promoted carbocyclization of 
21 that presumably proceeds through the nucleophilic aromatic sub-
stitution of aryliodide with the amide enolate. 
 
Scheme 7. Diverged access to three distinct sets of indole-containing 
heterocycles from a single set of Ugi-adducts. 
Similarly to the last Liu process, a number of post-Ugi transformations 
directly employ the enolizable amide group (Scheme 8) as a conven-
ient nucleophilic reactive site, which is by default present in a typical 
Ugi adduct 5.  
 9 
 
Scheme 8. Enolizable amide group in a typical Ugi adduct. 
For example, Chauhan and co-workers disclosed an efficient route 
towards isoindolinones 26 via Ugi reaction followed by a Cu-catalyzed 
carbocyclization accompanied by a fragmentation process, leading to 
the loss of the isocyanide-originated amide moiety (Scheme 9).12 
 
Scheme 9. Synthesis of isoindolinones 26. 
Based on Liu’s and Chauhan’s precedents, our group has evaluated 
this chemistry with 2-chloronicotinic acid-derived Ugi adducts 28 as-
suming that an electrophilic imidoyl chloride motif could be a suitable 
reaction partner for the nucleophilic amide enolate. It was found that 
such adducts 28 indeed undergo base-promoted cyclization with con-
comitant cleavage of the isocyanide-originated amide group similarly 
to Chauhan’s process. Treatment of crude 2-chloronicotinic acid-
derived Ugi adduct 28 with K2CO3 under inert atmosphere at 110 °C 
led to the formation of 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 29, 
while analogous reaction performed under air atmosphere gives rise 
 10 
to the formation of oxidized 7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-
b]pyridin-5-one 30 (Scheme 10).13 
 
Scheme 10. Synthesis of 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-ones 
29 and 30. 
Complimentary to the above processes, it has been demonstrated 
that the Ugi adducts bearing triple bond also readily undergo analo-
gous amide enolization-driven cycloisomerizations. In 2010, El Kaïm, 
Grimaud and Wagschal described an efficient route towards highly 
substituted pyrrolo[2,3-d]pyrimidines 34 through an Ugi-
Smiles/Sonogashira sequence, followed by base-catalyzed intramo-
lecular cyclization (Scheme 11).14 
 11 
 
Scheme 11. Synthesis of pyrrolo[2,3-d]pyrimidines 34. 
In 2012, Polindara-García and Miranda developed a tBuOK-promoted 
alkyne-allene isomerization of propargylamine-derived Ugi-adducts 
followed by enolization and cyclization into 2,3-dihydropyrroles 38 
(Scheme 12).15 
 
Scheme 12. Synthesis of 2,3-dihydropyrroles 38. 
We have reasoned that the application of 3-substituted propiolic acids 
39 in combination with phenyl glyoxal 40a 16,17 might provide an inter-
esting extension to these methodologies, through the generation of 
Ugi adducts 41 (Scheme 13) that should be even more prone to 
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enolization-triggered cycloisomerizations due to the Michael-acceptor 
nature of a triple bond conjugated with an amide group and the pres-
ence of an additional electron-withdrawing group at the enolizable 
position. We were pleased to find that the proposed intermediates 41 
spontaneously cyclize into pyrrolones 42 which subsequently undergo 
retro-Claisen fragmentation into the final pyrrolones 4318 through 
cleavage of the benzoyl moiety (Scheme 13).  
 
Scheme 13. Synthesis of pyrrolones 43. 
A detailed study on the scope and limitation of this novel cascade 
transformation is outlined in the Chapter 2.19 
1.2. Merging the Ugi reaction and gold catalysis  
The triple-bond activation by coinage metal salts towards intramo-
lecular nucleophilic attack, resulting in hetero- or carbocyclization, 
has become one of the prevalent strategies in modern heterocyclic 
chemistry.20 Such processes not only provide an efficient entry to 
many common heterocycles,21 but also serve the goal of broadening 
the existing chemical space by leading to a large variety of hitherto 
unknown and structurally complex heterocyclic scaffolds22 that could 
be of great interest for medicinal chemistry. Several of these proce-
dures aim to synthesize medium-ring containing heterocycles23 that 
 13 
are of particular importance due to their large occurrence amongst 
natural and biologically active compounds. 
In this regard, our group has recently studied the application of 3-
substituted propiolic acids 39 in the four-component Ugi reaction. The 
generated adducts, bearing a triple-bond functionality, were employed 
in a variety of gold-catalyzed post-Ugi transformations providing an 
access to a wide range of interesting heterocycles. 
For example, our group has efficiently exploited the catalytic activity 
of cationic gold complexes in a diversity-oriented approach towards 
fused polycyclic spiroindolinones 46.24 This strategy combines 3-
substituted propiolic acids 39 with indole-3-carbaldehydes 44 to gen-
erate the Ugi adducts 45 featuring a unique ‘‘branched-handed’’ ar-
chitecture that subsequently undergo a cationic Au(I)-catalyzed dia-
stereoselective domino cyclization process involving exo-dig25 cycliza-
tion followed by intramolecular trapping of the resulting spiro interme-
diate 48 delivering the final product 46 (Scheme 14).26  
 
Scheme 14. Synthesis of polycyclic spiroindolinones 46. 
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Interestingly, placing the carbonyl group in the 2-position of the indole 
core 49, or employing benzo[b]thiophene-2-carbaldehyde 50, gave 
rise to other types of Ugi adducts 51 and 52 that are prone to 
Au(PPh3)OTf-catalyzed endo-dig cyclization, resulting in the formation 
of medium-ring containing azepinoindoles 53 and azepinobenzothio-
phenes 54 respectively (Scheme 15).27  
 
Scheme 15. Synthesis of azepinoindoles 53 and azepinobenzothio-
phenes 54. 
Another notable extension is obtained when the carbonyl group is put 
in the 4-position of the indole, resulting in the formation of Ugi ad-
ducts 56. Remarkably, the regioselectivety of their cycloisomerization 
could be efficiently controlled by the choice of a proper catalytic sys-
tem. Employing either a cationic Au(I)- or In(III)- catalyst, the ring clo-
sure was directed towards an endo-dig or an exo-dig cyclization re-
spectively, resulting in the formation of azocino[5,4,3-cd]indoles 57 
and azepino[5,4,3-cd]indoles 58 (Scheme 16).28 
 15 
 
Scheme 16. Synthesis of azocino[5,4,3-cd]indoles 57 and aze-
pino[5,4,3-cd]indoles 58. 
The nucleophilic properties of the indole core are responsible for the 
ability of the above substrates to undergo transition metal-catalyzed 
carbocyclizations. The same is true for various pyrrole-based sub-
strates. The pyrrole-2-carbaldehyde-derived Ugi products 60 have 
been successfully applied for the regioselective synthesis of pyr-
rolo[2,3-c]azepines 61 and pyrrolo[2,3-c]pyridines 62 via a Pt(II)-
/cationic Au(I)-catalysis switch (Scheme 17).29 
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Scheme 17. Synthesis of pyrrolo[2,3-c]azepines 61 and pyrrolo[2,3-
c]pyridines 62. 
It is well known that medium-sized rings are difficult to synthesize for 
enthalpic and entropic reasons. In this regard, our group has demon-
strated that even a complex 9-membered ring containing ben-
zo[b]pyrrolo[1,2-i][1,5]diazonine skeleton 65 could be assembled fol-
lowing an Ugi/cationic Au(I)-catalyzed triple-bond hydroarylation se-
quence, employing the exceptionally high nucleophilicity of the 2-
position of the pyrrole ring of Ugi-adduct 64 (Scheme 18).30 
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Scheme 18. Synthesis of benzo[b]pyrrolo[1,2-i][1,5]diazonines 65. 
Transition metal-catalyzed post-Ugi cycloisomerization processes are 
not limited to carbocyclizations. Nitrogen nucleophiles have also been 
validated through the synthesis of imidazo[1,4]diazepin-7-ones 68 
starting from 1H-imidazole-4-carbaldehyde-derived Ugi adducts 67 
(Scheme 19).31 Interestingly, both cationic Au(I) and Ag(I) catalysts 
were found competent to catalyze this post-Ugi heteroannulation.  
 
Scheme 19. Synthesis of imidazo[1,4]diazepin-7-ones 68. 
Coming back to indole nucleophiles, our group has a long-standing 
interest in utilizing its reactivity for cyclizations onto the triple bond. It 
started in 2009 when a microwave-assisted Hg(OTf)2-catalyzed in-
tramolecular alkyne hydroarylation reaction was disclosed for the syn-
thesis of variously substituted azocino[4,5-b]indoles 70 from propar-
 18 
gylamides 69, which were prepared by amide coupling reaction 
(Scheme 20).32 
 
Scheme 20. Synthesis of azocino[4,5-b]indoles 70 via microwave-
assisted Hg(OTf)2-catalyzed intramolecular alkyne hydroarylation. 
Since most of the inorganic and organic mercury compounds are 
highly toxic, an alternative catalytic system to replace Hg(OTf)2 in the 
above process was investigated resulting in the engagement into cat-
ionic Au(I) catalysis. With regard to azocino[4,5-b]indole 70 synthesis, 
the Au(PPh3)Cl/AgOTf catalytic system was found to be superior to 
the previously described Hg(OTf)2 catalyst, and hence the substrate 
scope of the process was significantly expanded (Scheme 21).33  
 
Scheme 21. Synthesis of azocino[4,5-b]indoles 70 via cationic Au(I)-
catalyzed intramolecular alkyne hydroarylation. 
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Simultaneously a diversity-oriented approach was developed towards 
the synthesis of densely decorated azocino[4,5-b]indoles of type 73, 
employing a sequential Ugi reaction/cationic Au(I)-catalyzed intramo-
lecular alkyne hydroarylation (Scheme 22).34 
 
Scheme 22. Synthesis of azocino[4,5-b]indoles 73. 
In the course of the synthesis of azocino[5,4-b]indoles 70 through a 
gold-catalyzed intramolecular triple bond hydroarylation33 (Scheme 
21) another potentially useful transformation was accidentally discov-
ered (Scheme 23). While the common pathway involved the carbocy-
clization of propargylamides 69 into 70, the substrate 74, bearing an 
alcohol functional group, yielded oxazepine 75 as the major product, 
along with minor amounts of morpholine 76 (Scheme 23).35  
 
 20 
 
Scheme 23. Unexpected formation of oxazepine 75. 
The studies described in Chapter 3 aim to extend the scope of this 
approach, in order to establish a general and selective entry to the 
oxazepine scaffold 75, starting from three different types of hydroxy-
propargylamide substrates 74, 79 and 81 derived from either amide 
coupling or four-component Ugi reactions (Scheme 24).36,37,38 
 21 
 
Scheme 24. Outline of the general strategy for the generation of oxa-
zepines 75. 
1.3. Heck-type post-Ugi transformations; towards diversity-
oriented synthesis of 3-benzazepines 
In many cases, the four-component Ugi reaction and the intramolecu-
lar Heck coupling proved to be valuable additions to each other. In 
2004, Gracias and co-workers combined an α,β-unsaturated carbox-
ylic acid (cyclic and acyclic) 82, 2-bromobenzaldehyde 83a, benzyl 
amine 3a, and benzyl isocyanide 4d to generate the Ugi adducts 84 
that were further cyclized into isoquinolines 85 upon the action of Pd 
catalysis (Scheme 25).39  
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Scheme 25. Synthesis of isoquinolines 85. 
Simultaneously, Yang and co-workers described an efficient two-step 
Ugi–Heck procedure for the synthesis of two other types of isoquino-
line scaffolds 88 and 90 (Scheme 26).40 In this case, the required Ugi 
adducts 87 and 89 were prepared by reacting allylamine 86 either 
with a 2-halobenzaldehyde 83 or with a 2-iodobenzoic acid 19 in the 
presence of other required Ugi components (Scheme 26). 
 
Scheme 26. Synthesis of isoquinoline derivatives 88 and 90. 
Reacting amine 91, featuring elongated linker between the amine and 
olefin functionalities, with 2-iodobenzoic acid 19a, benzaldehyde 2a 
and benzyl isocyanide 4d affords Ugi adduct 92. Subsequent intermo-
 23 
lecular Heck coupling efficiently assembles the 7-membered ring of 2-
benzazepine 93 (Scheme 27).39 
 
Scheme 27. Synthesis of 2-benzazepine 93. 
The 2,3,4,5-tetrahydro-1H-benzo[d]azepine commonly referred to as 
the 3-benzazepine is another related medium ring containing hetero-
cyclic system and a core structural element of many natural and bio-
logically active compounds (Figure 1).41 
 
Figure 1.  
For example, the 3-benzazepine core is present in many alkaloids 
(Figure 2) such as aphanorphine, isolated from the blue-green algae, 
Aphanizomenon flos-aquae,42 lennoxamine, originally isolated from 
the Chilean barberry, Berberis darwinii43, and cephalotaxine, originally 
isolated44 from Cephalotaxus drupacea and Cephalotaxus fortunei. 
These compounds inspired many synthetic chemists owing to their 
unique and challenging structural features.45,46,47 It should also be 
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stressed that, although so far no significant biological activity has 
been reported for all these alkaloids, several naturally occurring es-
ters of cephalotaxine do exhibit promising anticancer48 and antimalar-
ial49 properties. 
 
Figure 2. Alkaloids featuring a 3-benzazepine motif. 
Various 1-aryl-substituted 3-benzazepines have been explored as 
dopaminergic agents due to their high affinity to dopamine recep-
tors.50 The typical compound of this class, fenoldopam, is a first selec-
tive peripheral dopamine receptor agonist approved for clinical use to 
cure severe hypertension.51 Another important type of biological activ-
ity associated with 3-benzazepines is based on their interaction with 
the serotonine receptors.52 For example, lorcaserin is an efficient and 
selective 5-HT2C agonist and has been studied as an anorectic for the 
treatment of obesity.53 
 
 
 
 
 25 
 
Figure 3. Representative biologically active compounds featuring the 
3-benzazepine motif. 
3-Benzazepine has been used as a target motif for a large number of 
synthetic studies. Successful examples include various types of ring-
expansion reactions,54 insertion of allenes into the Pd−C bond of or-
tho-palladated phenethylamines55 and heterocyclizations involving 
either intramolecular reductive amination56 or transition metal-
catalyzed triple-bond hydroamination.57 Radical,58 Friedel-Crafts59 and 
Heck-type60 carbocyclizations are also among the most applied meth-
odologies for the 3-benzazepine assembly. 
In 1994 Tietze and Schimpf described an efficient route towards 3-
benzazepines 95 applying an intramolecular version of the reductive 
Heck reaction, also referred to as a formal triple bond hydroary-
ation.61,62,63,64 In this process, propargylamides of type 94 bearing an 
aryliodide moiety undergo regioselective 7-exo-dig carbocyclization 
mediated by a Pd catalyst, followed by reduction of the intermediate 
vinylpalladium species A with sodium formate (Scheme 28). In addi-
tion to the regioselectivity, the process is also stereoselective produc-
ing exclusively 3-benzazepines 95 with the Z-configuration of the ex-
ocyclic double bond. 
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Scheme 28. Synthesis of 3-benzazepines 95. 
Following the success of Tietze’s procedure our group has estab-
lished a more general protocol that utilizes readily accessible propar-
gylamides 97 derived from 3-substituted propiolic acids 39 and 2-
bromophenethylamines 96 for the synthesis of benzazepines 98 
(Scheme 29).65,66,67 
 
Scheme 29. Synthesis of 3-benzazepines 98. 
Subsequently we expanded this approach to the use of propargyla-
mine precursors 100 derived from a Cu(I)-catalyzed three-component 
coupling of an aldehyde 2, a terminal alkyne 99, and a 2-
bromophenethylamine 96, commonly referred to as A3-coupling,68,69 
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aiming to introduce diversity in the resulting 3-benzazepines 101 
(Scheme 30).70 
 
Scheme 30. Synthesis of 3-benzazepines 101. 
Looking for other unexplored possibilities, we envisaged that the four-
component Ugi reaction71 might provide us with a novel interesting 
family of propargylamide precursors 102 for the reductive Heck cy-
clization. 3-Benzazepines 103-106, featuring different substitution 
patterns and even more diversity points, could be achieved by varying 
substituents and shuffling the required functional groups in the com-
ponents of the Ugi reaction (Scheme 31). Chapter 4 is devoted to the 
investigation of the applicability of this Ugi/reductive Heck se-
quence72,73 for the diversity-oriented synthesis of 3-benzazepines. 
 
Scheme 31. Strategy towards 3-benzazepines 103-106. 
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Chapter 2 
This chapter is based on [Assembly of a 1H-Pyrrol-2(5H)-one 
Core through a Cascade Ugi Reaction/5-endo-dig Carbocycliza-
tion/Retro-Claisen Fragmentation Process, Anatoly A. Peshkov, 
Vsevolod A. Peshkov, Zhenghua Li, Olga P. Pereshivko, Erik V. 
Van der Eycken, European Journal of Organic Chemistry, 2014, 
6390–6393]. 
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2. Assembly of a 1H-Pyrrol-2(5H)-one Core through 
a Cascade Ugi Reaction/5-endo-dig Carbocycliza-
tion/Retro-Claisen Fragmentation Process 
 
In this chapter we present a novel cascade transformation involving 
Ugi reaction followed by 5-endo-dig carbocyclization and retro-
Claisen fragmentation providing an access to 1H-pyrrol-2(5H)-one 
core. The operating protocol is very similar to the typical Ugi reaction 
settings, while the overall outcome results from the application of a 3-
substituted propiolic acid and a phenylglyoxal as acid and aldehyde 
components, respectively. The utility of process is demonstrated 
through the synthesis of a small library of 5-oxo-2,5-dihydro-1H-
pyrrole-2-carboxamides. 
2.1. Results and discussion 
We have started the substrate scope investigation with a screening of 
various primary amines 3a-f in a combination with tetrolic acid (39a), 
tert-butyl isocyanide (4a) and phenylglyoxal (40a, monohydrate form). 
Carrying out these reactions in methanol at 80 °C for 24 h we were 
able to obtain desired pyrrolones 43a-f in good to high yields of 62-92 
% (Table 1, entries 1-6). Application of different 3-substituted propiolic 
acids 39b-d in combination with 3a, 4a and 40a in all cases allowed 
to maintain the good yields for the target products 43g-i (Table 1, en-
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tries 7-9). In contrast, isocyanide component showed very different 
performance ranging from good for cyclohexyl isocyanide (4b) to 
moderate for 1,1,3,3-tetramethylbutyl (4c) and benzyl (4d) isocya-
nides down to very poor for aromatic 4-methoxyphenyl isocyanide 
(4e) (Table 1, entries 10-13). Next we decided to probe methylglyoxal 
(40b, 40 wt. % in water) in place of phenylglyoxal (40a) in order to 
upgrade the atom economy of the process by sacrificing with a small-
er acetyl fragment rather than a bigger benzoyl. However, three rep-
resentative reactions with 40b gave substantially diminished yields of 
the desired products compared to the analogous reactions with 40a 
(Table 1, entries 14, 15 and 16 versus 1, 2 and 7 respectively). 
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Table 1. Scope and limitation of a cascade Ugi reaction / 5-endo-dig carbocyclization / retro-Claisen frag-
mentation.[a] 
 
Entry R
1
 (3) R
2
 (39) R
3
 (4) R
4
 (40) 43 Yield, %
[b]
 
1 Bn (3a) Me (39a) tBu (4a) Ph (40a) 43a 92 
2 PMB (3b) Me (39a) tBu (4a) Ph (40a) 43b 62 
3 Heptyl (3c) Me (39a) tBu (4a) Ph (40a) 43c 73 
4 Cyclopropyl (3d) Me (39a) tBu (4a) Ph (40a) 43d 72 
5 Cyclooctyl (3e) Me (39a) tBu (4a) Ph (40a) 43e 76 
6 
 
(3f) Me (39a) tBu (4a) Ph (40a) 43f 64 
7 Bn (3a) Et (39b) tBu (4a) Ph (40a) 43g 89 
8 Bn (3a) Pentyl (39c) tBu (4a) Ph (40a) 43h 80 
9 Bn (3a) Ph (39d) tBu (4a) Ph (40a) 43i 60 
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Table 1. (continued) 
 
Entry R
1
 (3) R
2
 (39) R
3
 (4) R
4
 (40) 43 Yield, %
[b]
 
10
[c]
 Bn (3a) Me (39a) Cyclohexyl (4b) Ph (40a) 43j 87 
11 Bn (3a) Me (39a) 1,1,3,3- 
Tetramethylbutyl (4c) 
Ph (40a) 43k 40 
12 Bn (3a) Me (39a) Bn (4d) Ph (40a) 43l 29 
13 Bn (3a) Me (39a) 4-MeOC6H4 (4e) Ph (40a) 43m 11 
14 Bn (3a) Me (39a) tBu (4a) Me (40b) 43a 68 
15 PMB (3b) Me (39a) tBu (4a) Me (40b) 43b 37 
16 Bn (3a) Et (39b) tBu (4a) Me (40b) 43g 50 
[a] Reactions were carried out on a 0.5 mmol scale in 2 ml of MeOH using equimolar amounts of starting materials. 
[b] Yield of isolated product. [c] The reaction was conducted at 60 °C. 
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From the point of view of the overall outcome, both methylglyoxal 
(40b) and phenylglyoxal (40a) are used in our process as formalde-
hyde surrogates. However, the control experiment with paraformalde-
hyde (107) yielded only acyclic Ugi-adduct 108 (Scheme 32), showing 
that the presence of the glyoxal-derived electron-withdrawing group is 
essential for the cyclization step and for the overall Ugi reaction / 5-
endo-dig carbocyclization / retro-Claisen fragmentation process. 
 
Scheme 32. Control experiment with paraformaldehyde 107. 
It is also worth highlighting that in one case we were able to trap and 
characterize unfragmented pyrrolone 42d. Conducting the reaction of 
39a, 40a, 3d, and 4a at 60 °C in the presence of anhydrous sodium 
sulfate led to the isolation of 42d in 33 % yield in addition to 43d, 
which was still obtained as a major product in 54 % yield (Scheme 
33). Compound 42d fully converts into 43d and benzoic acid during 
long term storage under ambient conditions. 
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Scheme 33. Trapping of pyrrolone 42d. 
2.2. Conclusions 
In conclusion, we have successfully combined elements of rational 
design and serendipity to elaborate a novel cascade transformation 
involving Ugi reaction followed by enolization-triggered 5-endo-dig 
carbocyclization and retro-Claisen fragmentation leading to 1H-pyrrol-
2(5H)-ones. The described methodology is operationally simple and 
utilizes readily available primary amines, 3-substituted propiolic acids, 
isocyanides and phenylglyoxal as starting materials. 
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Chapter 3 
This chapter is based on [Gold- and Silver-Catalyzed 7-endo-
dig Cyclizations for the Synthesis of Oxazepines, Anatoly A. 
Peshkov, Anton A. Nechaev, Olga P. Pereshivko, Jan L. Goe-
man, Johan Van der Eycken, Vsevolod A. Peshkov, Erik V. Van 
der Eycken, European Journal of Organic Chemistry, 2015, 
4190–4197]. 
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3. Gold and Silver Catalyzed 7-endo-dig Cycliza-
tions for the Synthesis of Oxazepines 
 
In this chapter we describe a comprehensive study on gold- and sil-
ver-catalyzed cycloisomerizations of hydroxypropargylamides into 
oxazepines. Three different types of hydroxypropargylamide sub-
strates derived from either amide coupling or Ugi reaction have been 
validated providing selective and general access to a medium-ring 
oxazepine core. 
3.1. Results and discussion 
We have started with the synthesis of several hydroxypropargyl-
amides 74 through the direct amide coupling of unprotected second-
ary aminoalcohols 77 with 3-substituted propiolic acids 39. All reac-
tions proceeded with moderate to good efficiency utilizing DCC as a 
convenient coupling reagent (Scheme 34). 
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Scheme 34. Synthesis of hydroxypropargylamides 74 through the 
amide coupling reaction. 
Another set of hydroxypropargylamide substrates 79 and 81 was at-
tained by a four-component Ugi reaction that at the same time acted 
as a potent diversification tool. Incorporating the hydroxyl function into 
the amine component yielded hydroxypropargylamides of type 79 
(Scheme 35a). The application of glycolaldehyde dimer 80 provided 
hydroxypropargylamides of type 81 (Scheme 35b). 
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Scheme 35. Synthesis of hydroxypropargylamides 79 and 81 through 
Ugi reaction. 
Next we performed a catalyst screening using hydroxypropargylamide 
74a as a model substrate (Table 2). The application of 
gold(I)triphenylphosphine chloride in combination with silver(I) triflate, 
forming in situ catalytically active cationic gold, led to a full conversion 
 42 
of 74a within 2 h at 25 °C allowing to obtain the desired oxazepine 
75a in 96 % isolated yield (Table 2, entry 1). Silver triflate alone was 
also competent to catalyze this transformation (Table 2, entries 2-4), 
although, an extended time and an elevated reaction temperature of 
50 °C were required to achieve full conversion of 74a, finally providing 
75a in 91 % isolated yield (Table 2, entry 4). At the same time 
gold(I)triphenylphosphine chloride alone, copper(II) triflate and p-
toluenesulfonic acid failed to catalyze this process (Table 2, entries 5, 
6 and 7). Applying gold(III) chloride, the desired oxazepine product 
75a could be obtained in moderate yield but it is difficult to drive reac-
tion to completion (Table 2, entries 8-10). Probably, the reaction 
slows down due to the degradation of the catalyst that occurs during 
prolonged reaction time. 
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Table 2. Catalyst screening for the cycloisomerization of hydroxypropargylamide 74a into oxazepine 75a.
[a]
 
 
Entry Catalyst Conditions Conversion [%]
[b]
 Yield [%]
[c]
 
1 (conditions A) 5 mol% Au(PPh3)Cl/AgOTf 2 h, 25 °C 100 96 
2 5 mol% AgOTf 24 h, 25 °C 82 78 
3 5 mol% AgOTf 2 h, 50 °C 93 85 
4 (conditions B) 5 mol% AgOTf 15 h, 50 °C 100 91 
5 5 mol% Au(PPh3)Cl 24 h, 25 °C or 3 h, 50 °C 0 0 
6 5 mol% Cu(OTf)2 24 h, 25 °C or 3 h, 50 °C 0 0 
7 20 mol% TsOH∙H2O 15 h, 50 °C 0 0 
8 5 mol% AuCl3 2 h, 25 °C 39 35 
9 5 mol% AuCl3 2 h, 50 °C 47 40 
10 5 mol% AuCl3 24 h, 50 °C 60 51 
[a] The reactions were run on 0.3 mmol scale in 1.2 mL of dry CHCl3. [b] Determined from 
1
H NMR of a crude reaction 
mixture. [c] Yield of isolated product.  
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With these results in hand, we explored the substrate scope. The cy-
cloisomerizations of all prepared hydroxypropargylamides 74, 79 and 
81 were attempted under both cationic gold (condition A) and silver 
triflate (condition B) catalysis in all cases delivering the target oxaze-
pines 75 in good to high yields with comparable efficiency (Table 3). 
Importantly, no racemization occurred in the reactions with substrates 
(S)-74b and (R)-74b derived from enantiopure prolinols, demonstrat-
ing the mild character of both gold- and silver-catalyzed protocols 
(Table 3, entries 1 and 2). For the silver-catalyzed cyclizations of hy-
droxypropargylamides 74c and 79f bearing a phenyl group on the tri-
ple bond, and hydroxypropargylamide 81a an increased catalyst load-
ing was required in order to reach full conversion (Table 3, entries 3, 
11 and 14). Finally, it is important to stress that all reaction exclusively 
led to the formation of oxazepine 75 via 7-endo-dig cycloisomeriza-
tion. 
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Table 3. Cycloisomerizations of hydroxypropargylamide precursors 74, 79 and 81 into oxazepines 75.[a] 
 
Entry 
Hydroxypropargylamide 74, 79  
or 81 
Oxazepine 75 
Yield [%]
[b]
 
Conditions A Conditions B 
1 
  
95 89 
2 
  
96 -
[c]
 
3 
  
73 74
[d]
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Table 3. (continued) 
Entry 
Hydroxypropargylamide 74, 79  
or 81 
Oxazepine 75 
Yield [%]
[b]
 
Conditions A Conditions B 
4 
  
84 86 
5 
  
90 86 
6 
  
89 89 
7 
  
75 64 
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Table 3. (continued) 
Entry 
Hydroxypropargylamide 74, 79  
or 81 
Oxazepine 75 
Yield [%]
[b]
 
Conditions A Conditions B 
8 
  
77 74 
9 
  
88 82 
10 
  
87 84 
11 
  
89 78
[d]
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Table 3. (continued) 
Entry 
Hydroxypropargylamide 74, 79  
or 81 
Oxazepine 75 
Yield [%]
[b]
 
Conditions A Conditions B 
12 
  
84 86 
13 
  
95 85 
14 
  
82
[e]
 89
[d]
 
15 
  
82 79 
[a] The reactions were run on 0.3 mmol scale in 1.2 mL of dry CHCl3. [b] Yield of isolated product. [c] The reaction was 
not performed. [d] 20 mol% of AgOTf was used and the reaction was run for 20 h. [e] The reaction was run for 16 h. 
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3.2. Conclusions 
In summary, we have successfully established an efficient and selec-
tive route towards the synthesis of oxazepines through the cycloi-
zomerization of readily accessible hydroxypropargylamides that oc-
curs in the presence of either gold or silver catalyst. The scope of the 
process has been thoroughly explored using various types of sub-
strates, resulting in the generation of a small yet diverse library of tar-
get compounds. 
 50 
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Chapter 4 
This chapter is based on [Diversification of the 3-benzazepine 
scaffold applying Ugi/reductive Heck sequence, Anatoly A. 
Peshkov, Vsevolod A. Peshkov, Olga P. Pereshivko, Erik V. 
Van der Eycken, Tetrahedron, 2015, 71, 3863–3871]. 
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4. Diversification of the 3-Benzazepine Scaffold 
Applying Ugi / Reductive Heck Sequence 
 
In this chapter, we evaluate a two-step sequence involving Ugi reac-
tion followed by reductive Heck cyclization in order to provide access 
to a 3-benzazepine framework in a diversity-oriented fashion. Several 
aspects related to the substrate scope and the optimal distribution of 
the required functional groups have been addressed, resulting in the 
construction of a small library of the title compounds, featuring four 
distinct types of substitution pattern. 
4.1. Results and discussion 
We have started our synthetic exercises with a straightforward com-
bination of 3-substituted propiolic acids 39 and 2-
bromophenethylamines 96 complemented with various aldehydes 2 
and isocyanides 4. In all cases the required propargylamide precur-
sors 102a-g and the final 3-benzazepines of type 103 could be suc-
cessfully prepared with good to high yields (Table 4). The substrate 
scope proved to be quite flexible allowing the successful application 
of both aliphatic and aromatic aldehydes 2 and isocyanides 4. In addi-
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tion both alkyl and aryl substituents at the 3-position of the propiolic 
acid 39 were found to be tolerable.  
Switching to the use of a ketone 109 as carbonyl component gave 
diminished 35% yield of Ugi product 102h despite the elevated reac-
tion temperature of 70 °C and extended reaction time of 72 h. None-
theless subsequent reductive Heck cyclization delivered 3-
benzazepine 103h in a fairly good yield of 56% (Scheme 36). 
Next we compared the reactivity of 2-bromo- and 2-
iodophenethylamines 96b and 96b’ as well as of corresponding pro-
pargylamides 102i and 102iʹ derived from them. The 2-
bromophenethylamine 96b beat the iodo- analog 96b’ in the Ugi step, 
while the 2-iodophenethylamine-derived propargylamide 102iʹ proved 
to be somewhat better then 102i in the reductive Heck ring-closure 
(Table 5). 
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Table 4. Ugi/reductive Heck sequence for the synthesis of 3-benzazepines of type 103.[a] 
 
Entry 
 
Propiolic acid 
39; R
6
 
 
2-bromophenethyl- 
amine 96; R
5
  
Aldehyde 
2; R
2 
Isocyanide  
4; R
4 
Ugi product 102 
(yield, %)
[b]
 
Reductive Heck pro-
duct 103 (yield, %)
[b]
 
1 Me H Pr Bn 102a (88) 103a (90) 
2 Me H 4-CNC6H4 1,1,3,3-
tetramethylbutyl 
102b (91) 103b (79) 
3 Me 4,5-(MeO)2 Ph tBu 102c (93) 103c (76) 
4 Et H iBu Cy 102d (93) 103d (77) 
5 Hexyl H iBu 2-naphthyl 102e (86) 103e (81) 
6 Ph 4,5-(MeO)2 Pr tBu 102f (80) 103f (87) 
7 4-MeOC6H4 H Bn tBu 102g (43) 103g (63) 
[a] The Ugi reactions were run on 0.5 mmol scale in 2 mL of MeOH; the reductive Heck reactions were run on 0.15-0.45 mmol 
scale. [b] Yield of isolated product.  
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Scheme 36. Use of a ketone as carbonyl component in the Ugi/reductive Heck sequence. 
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Table 5. Comparison of 2-bromo- and 2-iodophenethylamines 96b and 96b’ in the Ugi/reductive Heck se-
quence.[a] 
 
Entry X Ugi reaction time, h Ugi product (yield, %)
[b]
 Reductive Heck t, °C 
Reductive Heck 
product (yield, %)
[b]
 
1 Br 24 102i (71) 110 103i (79) 
2 I 48 102iʹ (46) 90 103i (91) 
[a] The Ugi reactions were run on 0.5 mmol scale in 2 mL of MeOH; the reductive Heck reactions were run on 0.2 mmol scale. 
[b] Yield of isolated product.  
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Moving the bromoaryl functionality from the amine to the aldehyde 
component while maintaining the propiolic acids as source of the tri-
ple bond provided another interesting type of Ugi adducts 102j-l. The 
subsequent reductive Heck cyclization resulted in the efficient syn-
thesis of densely decorated 3-benzazepines of type 104 in up to 95% 
yield (Table 6).  
When a primary propargylamine 111a was used as triple bond source 
in combination with 2-bromophenylacetaldehyde 110, benzoic acid 1a 
and tert-butyl isocyanide 4a a moderate yield of 56% for the Ugi ad-
duct 102m was obtained. The subsequent conversion into the target 
3-benzazepine 105 gave 49% yield (Scheme 37).  
Finally, the triple bond was delivered by the primary propargylamine 
111 and the arylbromide moiety by the carboxylic acid 112. This 
combination proved to be the most unfavorable as already the Ugi 
step proceeded with just a moderate efficiency. More disappointedly, 
the crucial reductive Heck step gave the desired benzazepines 106 in 
low yields of 24% and 31%, despite the full conversion of the starting 
propargylamides 102n,o (Table 7).  
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Table 6. Ugi/reductive Heck sequence for the synthesis of 3-benzazepines of type 104.[a] 
 
Entry 
 
Propiolic acid 
39; R
6
 
Amine 3; R
3 
 
Isocyanide 4; R
4 
 
Ugi product 102 
(yield, %)
[b]
 
Reductive Heck  
product 104 (yield, %)
[b]
 
1 Me Bn Cy 102j (63) 104a (95) 
2 Et Cyclopropyl 4-MeOC6H4 102k (70) 104b (77) 
3 Ph Pentyl tBu 102l (66) 104c (88) 
[a] The Ugi reactions were run on 0.5 mmol scale in 2 mL of MeOH; the reductive Heck reactions were run on 0.2-0.3 mmol 
scale. [b] Yield of isolated product.  
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Scheme 37. Ugi/reductive Heck sequence for the synthesis of 3-benzazepine 105. 
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Table 7. Ugi/reductive Heck sequence for the synthesis of 3-benzazepines of type 106. 
 
Entry 
 
Propargylamine 111; R
7
, R
8 
 
Aldehyde 2; R
2 
 
Ugi product 102  
(yield, %) 
Reductive Heck  
product 106 (yield, %) 
1 H, Ph Pr 7n (52)
[a]
 11a (24)
[b]
 
2 Me, 4-ClC6H4 4-FC6H4 7o (33)
[c]
 11b (31)
[c]
 
[a] Yield of crude product.  
[b] Yield of isolated product calculated based on crude starting material.  
[c] Yield of isolated product. 
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Scheme 38. Proposed mechanistic pathway of the reductive Heck 
reaction 
A possible pathway for the intramolecular reductive Heck reaction ex-
emplified by the synthesis of 3-benzazepine 103a is presented on 
Scheme 38. The starting Ugi adduct 102a undergoes oxidative addi-
tion to the palladium (0) catalyst followed by the formation of the ar-
ylpalladium π-complex A. In the next step, A is transformed into a vi-
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nyl palladium complex B via simultaneous syn-insertion of the triple 
bond. This is followed by the ligand exchange, extrusion of CO2 and 
the reductive elimination providing final 103a. As can be evident from 
the mechanism, this strategy exclusively provides exo-cyclized seven-
membered products possessing the Z-configuration of the exocyclic 
double bond. The endo-cyclization via a hypothetical intermediate C 
is fairly unlikely due to the high strain exerted by the trans geometry 
around the double bond in the medium-sized ring. Importantly, the 
structure of the representative 3-benzazepine synthesized by this 
methodology has been previously unambiguously assigned using 
COSY, HMBC, HMQC and NOE NMR techniques.41d,55a 
4.2. Conclusions 
In summary, we have demonstrated that the Ugi reaction could be 
successfully applied for the synthesis of various propargylamides that 
are suitable substrates for the reductive Heck cyclization leading to 
the 3-benzazepine scaffold. Four different types of 3-benzazepines 
were assembled showing that the overall efficiency of the process 
significantly depends on the initial distribution of the required func-
tional groups in the Ugi reaction components. 
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General conclusions 
and perspectives 
The work described in this thesis belongs to one of the major re-
search program pursued by our group that is devoted to the diversity-
oriented synthesis of biologically important heterocycles. The core 
concept of this work is to highlight and broaden the synthetic potential 
of 3-substituted propiolic acids in a four-component Ugi reaction. This 
interest was driven by multiple possibilities of upgrading the resulting 
Ugi-adducts into heterocycles that arise from the presence of the pro-
piolic acid-originated triple bond and, if necessary, other functionali-
ties. 
In the first project (Chapter 2) we have efficiently extended the array 
of enolization-driven post-transformations of Ugi adducts by a novel 
one-pot cascade Ugi reaction / 5-endo-dig carbocyclization / retro-
Claisen fragmentation process leading to 1H-pyrrol-2(5H)-ones. The 
operating protocol for this process is very similar to the typical Ugi 
reaction settings, while the overall outcome results from the applica-
tion of a 3-substituted propiolic acid and a phenylglyoxal as acid and 
aldehyde components, respectively.  
Following our long-standing interests in medium ring systems as well 
as in the activation of the triple bond by a coinage metal salts we in-
voked Ag(I)- and cationic Au(I) catalysis to establish a general route 
towards oxazepine core through the cycloizomerizations of hydroxy-
propargylamides derived from either Ugi reaction or amide coupling 
(Chapter 3).  
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Finally, in the last project (Chapter 4) we extended the applicability of 
our reductive Heck procedure leading to 3-benzazepine scaffold to 
the use of Ugi reaction-derived propargylamides that helped to 
achieve an exceptionally high level of diversity in the resulting library 
of target products.  
Thus, it can be assumed that with regard to propiolic acid-derived Ugi 
adducts, the main goal of this thesis was successfully achieved, as 
they indeed proved to allow a large variety of post-transformations, 
which spands from classical enolization-driven cycloisomerizations 
(Chapter 2) to more modern Pd(0)-, Ag(I)- and cationic Au(I)-
catalyzed transformations (Chapers 3 and 4). 
With regard to the scope, it is rather clear that the four-component 
Ugi reaction already offers tremendous potential for diversification. 
Furthermore, we have shown that shuffling the required functional 
groups in the components of the Ugi reaction leads to altering the 
substitution pattern in the desired heterocyclic scaffolds (Chapers 3 
and 4), opening the way to the concept of ‘‘libraries of libraries’’ of 
products resembling natural products and pharmaceuticals. There-
fore, these current findings not only complement the existing array of 
synthetic approaches but also offer some concepts that are important 
for designing and implementing further strategies.  
The next task would be to transfer some of these methodologies to a 
three-component Passerini reaction.74 This proved to be somewhat 
challenging as our initial attempt to substitute the Ugi reaction with a 
Passerini reaction in the enolization-triggered cyclization, described in 
Chapter 2, met with failure, as a complex mixture of reaction products 
was obtained. However, when we switched from phenylglyoxal (40a) 
to ethyl glyoxylate (113) the formation of both Ugi 114 and Passerini 
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116 adducts could be successfully observed. To our delight these ad-
ducts could be in situ converted into 1H-pyrrol-2(5H)-ones 115 and 
butenolides 117, respectively (Scheme 39). The study of the scope 
and limitations of these new processes are currently underway. 
 
Scheme 39. Multicomponent Ugi and Passerini reactions in the tan-
dem processes leading to 1H-pyrrol-2(5H)-ones 115 and butenolides 
117. 
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Experimental part 
General information  
1H and 13C NMR spectra were recorded with 300 and 75 MHz respec-
tively using Bruker Avance instrument. The 1H and 13C chemical shifts 
are reported in parts per million relative to tetramethylsilane using the 
residual solvent signal as the internal reference.  
The microwave irradiation experiments were carried out in a dedicat-
ed CEM-Discover monomode microwave apparatus, operating at a 
frequency of 2.45 GHz with continuous irradiation power from 0 to 
300 W and utilization of the standard absorbance level of 300 W. The 
reactions were carried out in 10 mL glass tubes, sealed with a Teflon 
septum and placed in the microwave cavity. The reactions were irra-
diated at the required set temperature for the stipulated time and then 
cooled to ambient temperature with air jet cooling. 
Low resolution mass spectra were recorded using a Hewlett-Packard 
5989A mass spectrometer (EI and CI mode).  
High-resolution EI mass spectra were recorded on a Kratos MS50TC 
system with a resolution of 10000. The ion source temperature was 
150-250 °C, as required.  
High-resolution ESI mass spectra for Chapter 3 were recorded using 
an Agilent 1100 series HPLC coupled to an Agilent 6220A TOF-MSD, 
equipped with ESI/APCI ionization source.  
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High-resolution ESI mass spectra for Chapter 4 were acquired on a 
quadrupole orthogonal acceleration time-of-flight mass spectrometer 
(Synapt G2 HDMS, Waters, Milford, MA). Samples were infused at 3 
µL/min and spectra were obtained in positive ionization mode with a 
resolution of 15000 (FWHM) using leucine enkephalin as lock mass.  
Reversed phase HPLC separation was performed on a Waters Delta 
600 analytical/preparative system equipped with a Waters 996 Photo 
Diode Array detector using Alltech C18 Prevail (5 µm×150 nm×22 
mm) preparative column.  
Infrared (IR) spectra were recorded neat on a Bruker ALPHA FT-IR 
Spectrometer, and wavelengths are reported in cm-1. 
Specific rotations were measured using PolAAr 20 automatic polar-
imeter. 
Melting points were recorded on a Reichert Thermovar apparatus and 
are uncorrected. 
All required reagents, starting materials and solvents were purchased 
from commercial sources and used without further purification. 
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Chapter 2 
General procedure for the Ugi reaction followed by 5-endo-
dig carbocyclization and retro-Claisen fragmentation  
3-Substituted propiolic acid 39 (0.5 mmol) was dissolved in methanol 
(2 mL) followed by addition of phenylglyoxal monohydrate (40a) (76 
mg, 0.5 mmol), amine 3 (0.5 mmol) and isocyanide 4 (0.5 mmol). The 
resulting mixture was stirred at 80 °C for 24 h in a sealed screw cap 
vial. The resulting mixture was concentrated and subjected to the col-
umn chromatography to give desired product 43.  
 
1-benzyl-N-tert-butyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrole-2-
carboxamide (43a). The title compound (132 mg, 92 %) was isolated 
by column chromatography on silicagel using heptane-EtOAc (40 %) 
as eluent. 1H NMR (300 MHz, CDCl3): δ 7.41-7.13 (m, 5H), 5.91 
(pentet, J = 1.5 Hz, 1H), 5.47 (bs, 1H), 4.82 (d, J = 14.8 Hz, 1H), 4.27 
(d, J = 14.8 Hz, 1H), 4.22-4.17 (m, 1H), 2.05-2.00 (m, 3H), 1.20 (s, 
9H); 13C NMR (CDCl3, 75 MHz): δ 173.2, 165.5, 157.2, 136.9, 129.1, 
128.6, 128.1, 122.3, 71.3, 51.6, 46.1, 28.5, 14.6; HRMS (EI, [M]+) for 
C17H22N2O2
•+ calcd. 286.1676, found 286.1674. 
 
 72 
 
N-tert-butyl-1-(4-methoxybenzyl)-3-methyl-5-oxo-2,5-dihydro-1H-
pyrrole-2-carboxamide (43b). The title compound (98 mg, 62 %) 
was isolated by column chromatography on basic alumina using hep-
tane-EtOAc (50-70 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 7.22-
7.14 (m, 2H), 6.87-6.80 (m, 2H), 5.87 (pentet, J = 1.5 Hz, 1H), 5.45 
(bs, 1H), 4.78 (d, J = 14.7 Hz, 1H), 4.21-4.11 (m, 2H), 3.78 (s, 3H), 
2.02-1.98 (m, 3H), 1.21 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 173.1, 
165.6, 159.5, 157.1, 130.0, 129.0, 122.3, 114.4, 71.1, 55.4, 51.6, 
45.4, 28.5, 14.6; HRMS (EI, [M]+) for C18H24N2O3
•+ calcd. 316.1781, 
found 316.1817. 
 
N-tert-butyl-1-heptyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrole-2-
carboxamide (43c). The title compound (107 mg, 73 %) was isolated 
by column chromatography on basic alumina using heptane-EtOAc 
(50-70 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 5.82 (pentet, J = 
1.5 Hz, 1H), 5.58 (bs, 1H), 4.35-4.28 (m, 1H), 3.67 (dt, J = 8.0, 13.9 
Hz, 1H), 3.05-2.90 (m, 1H), 2.07-1.98 (m, 3H), 1.59-1.44 (m, 2H), 
1.33-1.14 (m, 17H), 0.90-0.77 (m, 3H); 13C NMR (CDCl3, 75 MHz): δ 
172.9, 166.0, 156.2, 122.7, 71.3, 51.7, 41.8, 31.8, 29.0, 28.7, 28.4, 
26.9, 22.6, 14.4, 14.1; HRMS (EI, [M]+) for C17H30N2O2
•+ calcd. 
294.2302, found 294.2307. 
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N-tert-butyl-1-cyclopropyl-3-methyl-5-oxo-2,5-dihydro-1H-
pyrrole-2-carboxamide (43d). The title compound (85 mg, 72 %) 
was isolated by column chromatography on basic alumina using hep-
tane-EtOAc (50 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 5.81 
(pentet, J = 1.5 Hz, 1H), 5.51 (bs, 1H), 4.24-4.19 (m, 1H), 2.75-2.62 
(m, 1H), 2.04-1.99 (m, 3H), 1.32 (s, 9H), 0.90-0.64 (m, 4H); 13C NMR 
(CDCl3, 75 MHz): δ 174.0, 166.2, 156.5, 122.9, 72.2, 51.8, 28.7, 25.0, 
14.5, 5.3, 5.2; HRMS (EI, [M]+) for C13H20N2O2
•+ calcd. 236.1519, 
found 236.1515. 
 
N-tert-butyl-1-cyclooctyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrole-
2-carboxamide (43e). The title compound (116 mg, 76 %) was iso-
lated by column chromatography on basic alumina using heptane-
EtOAc (20-40 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 5.80 
(pentet, J = 1.5 Hz, 1H), 5.61 (bs, 1H), 4.37-4.31 (m, 1H), 4.07-3.91 
(m, 1H), 2.03-1.97 (m, 3H), 1.97-1.42 (m, 14H), 1.30 (s, 9H); 13C 
NMR (CDCl3, 75 MHz): δ 173.6, 167.1, 156.9, 123.3, 70.8, 54.6, 51.6, 
32.2, 31.9, 28.6, 26.7, 26.3, 26.0, 25.6, 24.4, 14.3; HRMS (EI, [M]+) 
for C18H30N2O2
•+ calcd. 306.2302, found 306.2302. 
 74 
 
1-(2-(1H-indol-3-yl)ethyl)-N-tert-butyl-3-methyl-5-oxo-2,5-dihydro-
1H-pyrrole-2-carboxamide (43f). The title compound (108 mg, 64 %) 
was isolated by column chromatography on basic alumina using 
EtOAc as eluent. 1H NMR (300 MHz, CDCl3): δ 8.25 (bs, 1H), 7.65-
7.56 (m, 1H), 7.39-7.31 (m, 1H), 7.23-7.15 (m, 1H), 7.15-7.06 (m, 
2H), 5.87 (pentet, J = 1.5 Hz, 1H), 5.50 (bs, 1H), 4.30-4.24 (m, 1H), 
4.12-3.98 (m, 1H), 3.54-3.38 (m, 1H), 3.15-2.93 (m, 2H), 2.04-1.97 
(m, 3H), 1.21 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 173.3, 166.0, 
156.7, 136.4, 127.4, 122.7, 122.3, 121.9, 119.7, 118.8, 112.6, 111.4, 
71.8, 51.7, 42.2, 28.5, 24.3, 14.4; HRMS (EI, [M]+) for C20H25N3O2
•+ 
calcd. 339.1941, found 339.1969. 
 
1-benzyl-N-tert-butyl-3-ethyl-5-oxo-2,5-dihydro-1H-pyrrole-2-
carboxamide (43g). The title compound (134 mg, 89 %) was isolated 
by column chromatography on silicagel using heptane-EtOAc (40-50 
%) as eluent. 1H NMR (300 MHz, CDCl3): δ 7.39-7.20 (m, 5H), 5.90 
(q, J = 1.7 Hz, 1H), 5.51 (bs, 1H), 4.81 (d, J = 14.9 Hz, 1H), 4.33-4.22 
(m, 2H), 2.40-2.27 (m, 2H), 1.19 (s, 9H), 1.16 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 75 MHz): δ 173.2, 165.6, 163.2, 136.9, 129.1, 128.6, 
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128.0, 120.3, 70.6, 51.6, 46.0, 28.4, 21.9, 11.8; HRMS (EI, [M]+) for 
C18H24N2O2
•+ calcd. 300.1832, found 300.1844. 
 
1-benzyl-N-tert-butyl-5-oxo-3-pentyl-2,5-dihydro-1H-pyrrole-2-
carboxamide (43h). The title compound (137 mg, 80 %) was isolated 
by column chromatography on basic alumina using heptane-EtOAc 
(20-40 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 7.39-7.18 (m, 5H), 
5.89 (q, J = 1.6 Hz, 1H), 5.51 (bs, 1H), 4.80 (d, J = 14.9 Hz, 1H), 4.29 
(d, J = 14.9 Hz, 1H), 4.24 (d, J = 1.4 Hz, 1H), 2.38-2.23 (m, 2H), 1.68-
1.43 (m, 2H), 1.38-1.21 (m, 4H), 1.19 (s, 9H), 0.95-0.78 (m, 3H); 13C 
NMR (CDCl3, 75 MHz): δ 173.2, 165.6, 161.9, 137.0, 129.1, 128.5, 
128.0, 120.9, 70.6, 51.5, 46.0, 31.4, 28.4, 27.2, 22.4, 14.0; HRMS (EI, 
[M]+) for C21H30N2O2
•+ calcd. 342.2302, found 342.2301. 
 
1-benzyl-N-tert-butyl-5-oxo-3-phenyl-2,5-dihydro-1H-pyrrole-2-
carboxamide (43i). The title compound (105 mg, 60 %) was isolated 
by column chromatography on basic alumina using heptane-EtOAc 
(20-40 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 7.61-7.51 (m, 2H), 
7.42-7.24 (m, 8H), 6.48 (d, J = 1.2 Hz, 1H), 5.37 (bs, 1H), 5.08 (d, J = 
14.9 Hz, 1H), 4.81 (d, J = 1.2 Hz, 1H), 4.18 (d, J = 14.9 Hz, 1H), 1.11 
(s, 9H); 13C NMR (CDCl3, 75 MHz): δ 171.4, 165.5, 155.9, 136.7, 
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130.7, 130.6, 129.00, 128.95, 128.7, 128.0, 127.1, 120.7, 68.8, 51.7, 
45.3, 28.3; HRMS (EI, [M]+) for C22H24N2O2
•+ calcd. 348.1832, found 
348.1842. 
 
1-benzyl-N-cyclohexyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrole-2-
carboxamide (43j). The reaction was conducted at 60 °C. The title 
compound (136 mg, 87 %) was isolated by column chromatography 
on silicagel using heptane-EtOAc (40-60 %) as eluent. 1H NMR (300 
MHz, CDCl3): δ 7.41-7.12 (m, 5H), 6.05 (d, J = 8.2 Hz, 1H), 5.90 
(pentet, J = 1.5 Hz, 1H), 5.02 (d, J = 14.9 Hz, 1H), 4.30-4.24 (m, 1H), 
4.07 (d, J = 14.9 Hz, 1H), 3.79-3.59 (m, 1H), 2.06-1.99 (m, 3H), 1.86-
1.53 (m, 5H), 1.41-0.93 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ 173.0, 
165.4, 157.0, 136.6, 129.0, 128.4, 128.0, 122.3, 70.0, 48.7, 45.5, 
32.8, 25.4, 25.01, 24.95, 14.5; HRMS (EI, [M]+) for C19H24N2O2
•+ 
calcd. 312.1832, found 312.1829. 
 
1-benzyl-3-methyl-5-oxo-N-(2,4,4-trimethylpentan-2-yl)-2,5-
dihydro-1H-pyrrole-2-carboxamide (43k). The title compound (68 
mg, 40 %) was isolated by column chromatography on basic alumina 
using heptane-EtOAc (30 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 
7.39-7.18 (m, 5H), 5.89 (pentet, J = 1.5 Hz, 1H), 5.58 (bs, 1H), 4.90 
(d, J = 14.9 Hz, 1H), 4.24-4.14 (m, 2H), 2.06-1.99 (m, 3H), 1.62 (d, J 
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= 15.0 Hz, 1H), 1.43 (d, J = 15.0 Hz, 1H), 1.34 (s, 3H), 1.23 (s, 3H), 
0.93 (s, 9H); 13C NMR (CDCl3, 75 MHz): δ 173.2, 165.1, 157.2, 136.9, 
129.2, 128.6, 128.1, 122.2, 71.2, 55.8, 52.5, 46.0, 31.7, 31.6, 28.8, 
28.3, 14.8; HRMS (EI, [M]+) for C21H30N2O2
•+ calcd. 342.2302, found 
342.2293. 
 
N,1-dibenzyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrole-2-
carboxamide (43l). The title compound (47 mg, 29 %) was isolated 
by column chromatography on basic alumina using heptane-EtOAc 
(10-50 %) as eluent. 1H NMR (300 MHz, CDCl3): δ 7.36-7.23 (m, 6H), 
7.23-7.12 (m, 4H), 6.74 (t, J = 5.8 Hz, 1H), 5.79 (pentet, J = 1.5 Hz, 
1H), 5.00 (d, J = 14.9 Hz, 1H), 4.42 (dd, J = 6.1 Hz, 1H), 4.36-4.24 
(m, 2H), 4.01 (d, J = 14.9 Hz, 1H), 2.03-1.99 (m, 3H); 13C NMR 
(CDCl3, 75 MHz): δ 172.9, 166.4, 156.7, 137.9, 136.4, 129.1, 128.9, 
128.5, 128.1, 127.9, 127.8, 122.5, 69.8, 45.5, 43.6, 14.6; HRMS (EI, 
[M]+) for C20H20N2O2
•+ calcd. 320.1519, found 320.1563. 
 
1-benzyl-N-(4-methoxyphenyl)-3-methyl-5-oxo-2,5-dihydro-1H-
pyrrole-2-carboxamide (43m). The pure title compound (18 mg, 11 
%) was obtained after column chromatography on basic alumina with 
ether-EtOAc (75 %) as eluent followed by column chromatography on 
silicagel with heptane-EtOAc (75 %) as eluent. 1H NMR (300 MHz, 
 78 
CDCl3): δ 8.06 (bs, 1H), 7.43-7.19 (m, 7H), 6.88-6.78 (m, 2H), 5.94 
(pentet, J = 1.5 Hz, 1H), 5.04 (d, J = 14.9 Hz, 1H), 4.45-4.39 (m, 1H), 
4.25 (d, J = 14.9 Hz, 1H), 3.79 (s, 3H), 2.11-2.07 (m, 3H); 13C NMR 
(CDCl3, 75 MHz): δ 173.2, 164.4, 157.0, 156.9, 136.4, 130.3, 129.2, 
128.6, 128.2, 122.6, 121.9, 114.2, 70.8, 55.6, 45.9, 14.7; HRMS (EI, 
[M]+) for C20H20N2O3
•+ calcd. 336.1468, found 336.1503. 
Control experiment with paraformaldehyde 
Tetrolic acid (39a) (84 mg, 1 mmol) and paraformaldehyde (107) (30 
mg) were dissolved in methanol (4 mL) followed by addition of ben-
zylamine (3a) (107 mg, 1 mmol) and tert-butyl isocyanide (4a) (83 mg, 
1 mmol). The resulting mixture was stirred at 80 °C for 24 h in a 
sealed screw cap vial. The resulting mixture was concentrated and 
subjected to the column chromatography to give Ugi adduct 108 (238 
mg, 83 %). 
 
N-benzyl-N-(2-(tert-butylamino)-2-oxoethyl)but-2-ynamide (108). 
Mixture of rotamers ~ 2:1.75 1H NMR (300 MHz, CDCl3): 7.42-7.22 (m, 
5H), 5.97 (bs, 0.67H), 5.38 (bs, 0.33H), 4.88 (s, 1.33H), 4.63 (s, 
0.67H), 4.05 (s, 0.67H), 3.80 (s, 1.33H), 2.04 (s, 2H), 1.99 (s, 1H), 
1.27 (s, 6H), 1.20 (s, 3H); 13C NMR (CDCl3, 75 MHz): δ 167.1, 166.9, 
155.5, 155.4, 136.3, 135.7, 129.1, 128.9, 128.8, 128.2, 128.1, 127.9, 
91.0, 90.9, 72.9, 72.7, 53.9, 53.3, 51.4, 51.3, 49.8, 49.4, 28.6, 28.4, 
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4.1, 4.0; MS(CI): m/z (relative intensity) 287 ([M+H]+, 82), 214 (100), 
172 (16).  
Trapping of the pyrrolone 42d 
Tetrolic acid (39a) (42 mg, 0.5 mmol) was dissolved in anhydrous 
methanol (2 mL) followed by addition of phenylglyoxal monohydrate 
(40a) (76 mg, 0.5 mmol), cyclopropylamine (3d) (29 mg, 0.5 mmol) 
and tert-butyl isocyanide (4a) (42 mg, 0.5 mmol). Then anhydrous 
Na2SO4 (0.5 g) was added and the mixture was stirred at 60 °C for 24 
h in a sealed screw cap vial. The Na2SO4 was filtered off and washed 
with EtOAc. The combined filtrate was gently concentrated under re-
duced pressure keeping the water bath of the rotovap at ambient 
temperature. Column chromatography on silicagel with heptane-
EtOAc (40-60 %) as eluent consecutively provided 42d (56 mg, 33 %) 
and 43d (64 mg, 54 %). 
 
2-benzoyl-N-tert-butyl-1-cyclopropyl-3-methyl-5-oxo-2,5-dihydro-
1H-pyrrole-2-carboxamide (42d). 1H NMR (300 MHz, CDCl3): δ 8.44 
(bs, 1H), 7.69-7.60 (m, 2H), 7.58-7.49 (m, 1H), 7.42-7.32 (m, 2H), 
6.18 (q, J = 1.5 Hz, 1H), 2.40-2.28 (m, 1H), 1.95 (d, J = 1.5 Hz, 3H), 
1.42 (s, 9H), 0.61-0.40 (m, 4H); 13C NMR (CDCl3, 75 MHz): δ 200.1, 
175.2, 162.6, 155.5, 137.6, 133.7, 128.8, 128.4, 126.6, 84.3, 52.2, 
28.6, 25.6, 13.5, 4.8, 4.7; HRMS (EI, [M]+) for C20H24N2O3
•+ calcd. 
340.1781, found 340.1827. 
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Chapter 3 
General Procedure for the Synthesis of hydroxypropargylamides 
74 through the amide coupling reaction 
3-Substituted propiolic acid (2.2 mmol) was dissolved in dry DCM (10 
mL) followed by addition of appropriate aminoethanol (2 mmol) and 
DCC (2.3 mmol). The resulting mixture was stirred at rt for 64 h in a 
sealed screw cap vial. The subsequently formed precipitate of N,N'-
dicyclohexylurea was filtered off and washed with DCM. The com-
bined organic layers were concentrated and subjected to column 
chromatography on silica gel.  
 
N-benzyl-N-(2-hydroxyethyl)but-2-ynamide (74a): Elution with hep-
tane/EtOAc (50→100%) delivered pure 74a as a ~ 3:7 mixture of ro-
tamers.75 Yield: 274 mg, 63%. 1H NMR (300 MHz, CDCl3): δ 7.45-
7.15 (m, 5H), 4.87 (s, 1.4H), 4.71 (s, 0.6H), 3.82-3.57 (m, 2.6H), 3.54-
3.07 (m, 2.4H), 2.08-1.93 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 
156.3, 155.5, 136.8, 136.3, 128.9, 128.7, 128.04, 127.96, 127.5, 90.3, 
89.9, 73.3, 73.2, 60.9, 60.5, 54.0, 50.2, 48.2, 47.4, 4.1; HRMS (EI): 
m/z [M]+ for C13H15NO2
•+ calcd. 217.1097; found 217.1118. 
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(S)-1-(2-(hydroxymethyl)pyrrolidin-1-yl)but-2-yn-1-one ((S)-74b): 
Elution with pure EtOAc delivered pure (S)-74b as a ~ 1:4 mixture of 
rotamers.75 Yield: 224 mg, 67%. 1H NMR (300 MHz, CDCl3): δ 4.70 
(bd, J = 6.1 Hz, 0.8H), 4.27-4.05 (m, 1H), 3.94-3.81 (m, 0.8H), 3.80-
3.50 (m, 3H), 3.50-3.37 (m, 0.2H), 2.98 (bs, 0.2H), 2.20-1.75 (m, 
6.2H), 1.74-1.58 (m, 0.8H); 13C NMR (75 MHz, CDCl3): δ 155.1, 
153.2, 89.7, 87.4, 74.4, 74.1, 66.4, 64.0, 61.1, 60.4, 49.7, 46.8, 28.7, 
27.7, 23.9, 22.6, 4.00, 3.97; HRMS (EI): m/z [M]+ for C9H13NO2
•+ 
calcd. 167.0941; found 167.0952. 
 
(R)-1-(2-(hydroxymethyl)pyrrolidin-1-yl)but-2-yn-1-one ((R)-74b): 
Elution with pure EtOAc delivered pure (R)-74b as a ~ 1:4 mixture of 
rotamers.75 Yield: 214 mg, 64%.  
 
N-benzyl-N-(2-hydroxyethyl)-3-phenylpropiolamide (74c): Elution 
with DCM/Et2O (20%) delivered pure 74c as a ~ 3:7 mixture of rota-
mers.75 Yield: 190 mg, 34%. 1H NMR (300 MHz, CDCl3): δ 7.59-7.27 
(m, 10H), 4.96 (s, 1.4H), 4.78 (s, 0.6H), 3.87-3.80 (m, 0.6H), 3.79-
3.70 (m, 2H), 3.60-3.53 (m, 1.4H); 13C NMR (75 MHz, CDCl3): δ 
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156.2, 155.3, 136.7, 136.2, 132.5, 132.4, 130.3, 130.1, 128.9, 128.7, 
128.55, 128.52, 128.14, 128.06, 127.64, 127.58, 120.4, 120.2, 91.3, 
90.9, 81.6, 81.5, 61.2, 60.8, 54.3, 50.5, 48.6, 47.8; HRMS (EI): m/z 
[M]+ for C18H17NO2
•+ calcd. 279.1254; found 279.1223. 
 
N-benzyl-N-(2-hydroxyethyl)pent-2-ynamide (74d): Elution with 
heptane/EtOAc (80%) delivered pure 74d as a ~ 3:7 mixture of rota-
mers.75 Yield: 180 mg, 39%. 1H NMR (300 MHz, CDCl3): δ 7.45-7.15 
(m, 5H), 4.87 (s, 1.4H), 4.72 (s, 0.6H), 3.82-3.74 (m, 0.6H), 3.73-3.59 
(m, 2H), 3.54-3.42 (m, 1.4H), 3.05 (bs, 1H), 2.44-2.29 (m, 2H), 1.25-
1.12 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 156.4, 155.5, 136.8, 
136.3, 128.8, 128.7, 128.1, 128.0, 127.6, 95.6, 95.1, 73.4, 73.3, 61.0, 
60.6, 54.1, 50.3, 48.4, 47.5, 12.83, 12.75, 12.69; HRMS (EI): m/z [M]+ 
for C14H17NO2
•+ calcd. 231.1254; found 231.1262. 
 
N-benzyl-N-(2-hydroxyethyl)oct-2-ynamide (74e): Elution with hep-
tane/EtOAc (50→80%) delivered pure 74e as a ~ 3:7 mixture of rota-
mers.75 Yield: 262 mg, 48%. 1H NMR (300 MHz, CDCl3): δ 7.41-7.18 
(m, 5H), 4.88 (s, 1.4H), 4.72 (s, 0.6H), 3.82-3.74 (m, 0.6H), 3.73-3.58 
(m, 2H), 3.53-3.42 (m, 1.4H), 2.39-2.27 (m, 2H), 1.65-1.44 (m, 2H), 
1.41-1.19 (m, 4H), 0.95-0.76 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 
156.4, 155.5, 136.8, 136.3, 128.8, 128.7, 128.1, 127.9, 127.52, 
127.47, 94.6, 94.1, 74.0, 73.9, 60.9, 60.7, 54.1, 50.3, 48.4, 47.5, 
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31.04, 30.95, 27.5, 27.3, 22.1, 22.0, 18.91, 18.89, 13.9, 13.8; HRMS 
(EI): m/z [M]+ for C17H23NO2
•+ calcd. 273.1723; found 273.1738. 
General Procedure for the Synthesis of hydroxypropargylamides 
79 through the Ugi reaction 
3-Substituted propiolic acid (1.5 mmol) was placed in a screw cap vial 
and dissolved in methanol (2 mL) followed by addition of aldehyde 
(1.5 mmol), ethanolamine (92 mg, 1.5 mmol) and isocyanide (1.5 
mmol). The mixture was stirred at room temperature for 24 h. Upon 
completion of reaction time the resulting mixture was diluted with 
DCM and evaporated with silica followed by column chromatography 
delivering pure 79. 
 
N-tert-butyl-2-(N-(2-hydroxyethyl)but-2-ynamido)pentanamide 
(79a): Elution with heptane/EtOAc/MeOH (50:50:1) delivered pure 
79a as a ~ 3:7 mixture of rotamers.75 Yield: 241 mg, 57%. 1H NMR 
(300 MHz, CDCl3): δ 6.51-6.21 (m, 1H), 4.62-4.46 (m, 0.3H), 4.38 (t, J 
= 7.8 Hz, 0.7H), 4.05-3.48 (m, 4H), 2.03 (s, 0.9H), 2.02 (s, 2.1H), 
1.99-1.70 (m, 2H), 1.43-1.21 (m, 11H), 1.02-0.90 (m, 3H); 13C NMR 
(75 MHz, CDCl3): δ 171.5, 169.7, 156.7, 156.0, 91.4, 90.7, 73.4, 73.3, 
63.3, 62.5, 61.2, 59.1, 51.7, 51.6, 50.1, 31.3, 30.2, 28.5, 28.4, 19.5, 
13.84, 13.78, 4.15, 4.12; HRMS (ESI): m/z [M+H]+ for C15H27N2O3
+ 
calcd. 283.2016; found 283.2020. 
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N-(1-(tert-butylamino)-1-oxopentan-2-yl)-N-(2-hydroxyethyl)pent-
2-ynamide (79b): Elution with heptane/EtOAc/MeOH (50:50:1) 
delivered pure 79b as a ~ 1:3 mixture of rotamers.75 Yield: 187 mg, 
42%. 1H NMR (300 MHz, CDCl3): δ 6.56 (bs, 0.25H), 6.42 (bs, 
0.75H), 4.60-4.47 (m, 0.25H), 4.41 (t, J = 7.8 Hz, 0.75H), 4.01-3.47 
(m, 4H), 2.47-2.31 (m, 2H), 1.99-1.57 (m, 2H), 1.44-1.14 (m, 14H), 
1.02-0.88 (m, 3H); 13C NMR (75 MHz, CDCl3, major rotamer): δ 
171.5, 156.1, 95.8, 73.4, 62.3, 59.1, 51.6, 49.9, 30.3, 28.4, 19.5, 13.8, 
12.70, 12.65; HRMS (ESI): m/z [M+H]+ for C16H29N2O3
+ calcd. 
297.2173; found 297.2175. 
 
N-(1-(cyclohexylamino)-1-oxopentan-2-yl)-N-(2-
hydroxyethyl)pent-2-ynamide (79c): Elution with hep-
tane/EtOAc/MeOH (50:50:1) delivered pure 79c as a ~ 1:3 mixture of 
rotamers.75 Yield: 290 mg, 60%. 1H NMR (300 MHz, CDCl3): δ 6.81 
(d, J = 6.7 Hz, 0.25H), 6.56 (d, J = 8.1 Hz, 0.75H), 5.12 (bs, 0.75H), 
4.73-4.59 (m, 0.25H), 4.45 (t, J = 7.8 Hz, 0.75H), 4.04-3.39 (m, 
5.25H), 2.46-2.30 (m, 2H), 2.20-1.50 (m, 7H), 1.45-1.05 (m, 10H), 
1.02-0.89 (m, 3H); 13C NMR (75 MHz, CDCl3, major rotamer): δ 
171.3, 156.0, 95.8, 73.4, 62.3, 58.8, 50.2, 48.6, 32.6, 32.5, 30.4, 25.4, 
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24.7, 19.5, 13.8, 12.71, 12.65; HRMS (EI): m/z [M]+ for C18H30N2O3
•+ 
calcd. 322.2251; found 322.2276. 
 
N-benzyl-2-(N-(2-hydroxyethyl)but-2-ynamido)pentanamide (79d): 
Elution with heptane/EtOAc/MeOH (60:40:1) delivered pure 79d as a 
~ 1:2 mixture of rotamers.75 Yield: 237 mg, 50%. 1H NMR (300 MHz, 
CDCl3): δ 7.48-7.11 (m, 5.33H), 6.94 (t, J = 5.5 Hz, 0.67H), 4.86-4.58 
(m, 1H), 4.54-4.31 (m, 2.67H), 3.99-3.35 (m, 4.33H), 2.20-2.03 (m, 
0.33H), 2.00 (s, 2H), 1.97-1.68 (m, 2.67H), 1.45-1.20 (m, 2H), 1.03-
0.88 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 172.2, 170.6, 156.9, 
156.1, 138.0, 137.7, 128.68, 128.65, 127.8, 127.6, 127.5, 91.7, 90.7, 
73.3, 73.2, 63.0, 62.0, 60.8, 58.9, 50.4, 43.74, 43.69, 31.4, 30.3, 19.6, 
19.5, 13.8, 13.7, 4.1, 4.0; HRMS (EI): m/z [M]+ for C18H24N2O3
•+ calcd. 
316.1781; found 316.1756. 
 
2-(N-(2-hydroxyethyl)but-2-ynamido)-N-(2,4,4-trimethylpentan-2-
yl)pentanamide (79e): Elution with heptane/EtOAc/MeOH (60:40:1) 
delivered pure 79e as a ~ 3:7 mixture of rotamers.75 Yield: 239 mg, 
47%. 1H NMR (300 MHz, CDCl3): δ 6.55-6.15 (m, 1H), 4.69-4.49 (m, 
0.3H), 4.40 (t, J = 7.6 Hz, 0.7H), 4.05-3.40 (m, 4H), 2.02 (s, 3H), 1.97-
1.55 (m, 4H), 1.46-1.21 (m, 8H), 1.05-0.90 (m, 12H); 13C NMR (75 
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MHz, CDCl3, major rotamer): δ 170.9, 156.0, 90.7, 73.3, 62.4, 59.3, 
55.7, 52.0, 50.2, 31.6, 31.4, 30.2, 28.7, 28.4, 19.5, 13.8, 4.1; HRMS 
(EI): m/z [M]+ for C19H34N2O3
•+ calcd. 338.2564; found 338.2597. 
 
N-tert-butyl-2-(N-(2-hydroxyethyl)-3-
phenylpropiolamido)pentanamide (79f): Elution with 
heptane/EtOAc/MeOH (70:30:1) delivered pure 79f as a ~ 1:3 mixture 
of rotamers.75 Yield: 233 mg, 45%. 1H NMR (300 MHz, CDCl3): δ 
7.64-7.49 (m, 2H), 7.48-7.30 (m, 3H), 6.68 (bs, 0.25H), 6.37 (bs, 
0.75H), 4.99 (bs, 0.75H), 4.65-4.30 (m, 1H), 4.12-3.43 (m, 4.25H), 
2.24-2.05 (m, 0.25H), 2.03-1.74 (m, 1.75 H), 1.47-1.21 (m, 11H), 0.98 
(t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 171.4, 169.7, 156.5, 
156.0, 132.6, 132.5, 130.5, 130.3, 128.64, 128.59, 120.1, 120.0, 92.0, 
91.6, 81.64, 81.56, 63.7, 62.5, 60.9, 59.4, 51.8, 51.6, 50.3, 31.7, 30.4, 
28.5, 19.8, 19.6, 13.88, 13.85; HRMS (EI): m/z [M]+ for C20H28N2O3
•+ 
calcd. 344.2094; found 344.2147. 
 
N-(1-(tert-butylamino)-1-oxo-3-phenylpropan-2-yl)-N-(2-
hydroxyethyl)but-2-ynamide (79g): Elution with 
heptane/EtOAc/MeOH (60:40:1) delivered pure 79g as a ~ 1:3 
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mixture of rotamers.75 Yield: 248 mg, 50%. 1H NMR (300 MHz, 
CDCl3): δ 7.36-7.11 (m, 5H), 6.70 (bs, 0.25H), 6.04 (bs, 0.75H), 4.91 
(bs, 0.75H), 4.47 (t, J = 8.0 Hz, 1H), 3.84-3.36 (m, 4.25H), 3.31-3.11 
(m, 1.75H), 2.83 (bs, 0.25H), 2.01 (s, 0.75H), 1.99 (s, 2.25H), 1.32 (s, 
2.5H), 1.25 (s, 7.5H); 13C NMR (75 MHz, CDCl3): δ 170.5, 168.9, 
156.1, 155.8, 137.6, 136.7, 129.2, 129.1, 128.7, 126.9, 126.8, 91.4, 
90.5, 73.7, 73.4, 65.6, 62.0, 61.6, 60.5, 51.7, 51.5, 51.2, 35.9, 34.3, 
28.4, 28.3, 4.2, 4.1; HRMS (ESI): m/z [M+H]+ for C19H27N2O3
+ calcd. 
331.2016; found 331.2019. 
 
N-tert-butyl-2-(N-(2-hydroxyethyl)but-2-ynamido)-4-
methylpentanamide (79h): Elution with heptane/EtOAc/MeOH 
(50:50:1) delivered pure 79h as a ~ 3:7 mixture of rotamers.75 Yield: 
369 mg, 83%. 1H NMR (300 MHz, CDCl3): δ 6.57-6.26 (m, 1H), 4.85-
4.44 (m, 1.7H), 4.08-3.40 (m, 4.3H), 2.04 (s, 0.9H), 2.02 (s, 2.1H), 
1.97-1.43 (m, 3H), 1.35 (s, 2.7H), 1.33 (s, 6.3H), 1.01-0.89 (m, 6H); 
13C NMR (75 MHz, CDCl3): δ 171.5, 169.7, 156.6, 156.1, 91.3, 90.7, 
73.7, 73.4, 73.3, 62.3, 61.5, 61.0, 56.9, 51.60, 51.57, 49.8, 38.1, 36.8, 
35.4, 28.5, 28.4, 24.8, 24.6, 23.1, 22.8, 22.3, 21.8, 4.10, 4.09; HRMS 
(EI): m/z [M]+ for C16H28N2O3
•+ calcd. 296.2094; found 296.2111. 
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General Procedure for the Synthesis of hydroxypropargylamides 
81 through the Ugi reaction 
Tetrolic acid (126 mg, 1.5 mmol) was placed in a screw cap vial and 
dissolved in methanol (2 mL) followed by addition of glycolaldehyde 
dimer (90 mg, 0.75 mmol), appropriate amine (92 mg, 1.5 mmol) and 
tert-butyl isocyanide (125 mg, 1.5 mmol). The mixture was stirred at 
room temperature for 24 h. Upon completion of reaction time the re-
sulting mixture was diluted with DCM and evaporated with silica fol-
lowed by column chromatography delivering pure 81. 
 
N-butyl-N-(1-(tert-butylamino)-3-hydroxy-1-oxopropan-2-yl)but-2-
ynamide (81a): Elution with heptane/EtOAc (50→80%) delivered 
pure 81a as a ~ 1:4 mixture of rotamers.75 Yield: 288 mg, 68%. 1H 
NMR (300 MHz, CDCl3): δ 6.66 (bs, 0.8H), 6.11 (bs, 0.2H), 4.81-4.72 
(m, 0.2H), 4.65 (t, J = 5.9 Hz, 0.8H), 4.22-4.10 (m, 0.2H), 4.09-3.96 
(m, 0.8), 3.96-3.53 (m, 3.6H), 3.52-3.39 (m, 0.2H), 3.17-3.03 (m, 
0.2H), 2.04 (s, 2.4H), 2.02 (s, 0.6H), 1.75-1.43 (m, 2H), 1.42-1.22 (m, 
11H), 1.00-0.83 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 169.5, 169.2, 
156.2, 156.0, 90.5, 90.3, 73.2, 63.3, 61.7, 60.8, 58.7, 51.8, 51.3, 48.1, 
44.8, 31.7, 30.4, 28.52, 28.49, 20.4, 20.0, 13.63, 13.55, 4.1, 4.0; 
HRMS (ESI): m/z [M+H]+ for C15H27N2O3
+ calcd. 283.2016; found 
283.2016. 
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N-(1-(tert-butylamino)-3-hydroxy-1-oxopropan-2-yl)-N-(4-
methoxybenzyl)but-2-ynamide (81b): Elution with heptane/EtOAc 
(50→80%) delivered pure 81b as a ~ 1:2 mixture of rotamers.75 Yield: 
208 mg, 40%. 1H NMR (300 MHz, CDCl3): δ 7.37-7.23 (m, 2H), 6.96-
6.80 (m, 2H), 6.07 (bs, 0.67H), 5.34 (bs, 0.33H), 5.13 (bd, J = 14.4 
Hz, 0.33H), 4.98 (d, J = 15.6 Hz, 0.67H), 4.72 (d, J = 15.6 Hz, 0.67H), 
4.53-4.19 (m, 1.33H), 4.10-3.91 (m, 1H), 3.80 (s, 2H), 3.79 (s, 1H), 
3.75-3.61 (m, 1H), 3.52 (bs, 0.67H), 3.36 (bs, 0.33H), 2.04 (s, 2H), 
1.99 (s, 1H), 1.19 (s, 6H), 1.15 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
169.0, 168.7, 159.5, 155.9, 130.0, 129.4, 129.1, 128.7, 114.5, 114.4, 
91.4, 91.2, 73.4, 73.3, 62.9, 61.7, 60.9, 59.6, 55.3, 52.2, 51.5, 51.3, 
35.4, 28.5, 28.2, 4.12, 4.09; HRMS (ESI): m/z [M+H]+ for C19H27N2O4
+ 
calcd. 347.1965; found 347.1960. 
General procedure for the gold-catalyzed cycloisomerization of 
hydroxypropargylamides 74, 79 and 81 into oxazepines 75 
(Conditions A) 
Hydroxypropargylamide 74, 79 or 81 (0.3 mmol) was dissolved in dry 
CHCl3 (1.2 mL) followed by addition of Au(PPh3)Cl (7.4 mg, 0.015 
mmol) and AgOTf (3.9 mg, 0.015 mmol). The resulting mixture was 
stirred at rt for 2-4 h in a sealed screw cap vial. The resulting mixture 
was concentrated under reduced pressure and loaded onto a silica 
gel column delivering pure 75. 
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General procedure for the silver-catalyzed cycloisomerization of 
hydroxypropargylamides 74, 79 and 81 into oxazepines 75 (Con-
ditions B) 
Hydroxypropargylamide 74, 79 or 81 (0.3 mmol) was dissolved in dry 
CHCl3 (1.2 mL) followed by addition of AgOTf (3.9 mg, 0.015 mmol). 
The resulting mixture was stirred at 50 °C for 15 h in a sealed screw 
cap vial. The resulting mixture was concentrated under reduced pres-
sure and loaded onto a silica gel column delivering pure 75. 
 
4-Benzyl-7-methyl-3,4-dihydro-1,4-oxazepin-5(2H)-one (75a): Elu-
tion with heptane/EtOAc (50→70%) provided pure 75a. Yield: 62.6 
mg, 96% (procedure A); 59.3 mg, 91% (procedure B). 1H NMR (300 
MHz, CDCl3): δ 7.40-7.12 (m, 5H), 5.21 (s, 1H), 4.63 (s, 2H), 4.22-
4.03 (m, 2H), 3.52-3.33 (m, 2H), 1.93 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 166.6, 160.3, 137.0, 128.7, 128.0, 127.5, 99.1, 71.4, 51.4, 
47.9, 22.6; HRMS (EI): m/z [M]+ for C13H15NO2
•+ calcd. 217.1097; 
found 217.1122. 
 
(S)-3-methyl-7,8,9,9a-tetrahydropyrrolo[2,1-c][1,4]oxazepin-5(1H)-
one ((S)-75b): Elution with pure EtOAc provided pure (S)-75b. Yield: 
47.7 mg, 95% (procedure A); 44.6 mg, 89% (procedure B). [α]D
20 = – 
80.1 (c = 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 5.10 (s, 1H), 4.39 
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(d, J = 11.7 Hz, 1H), 3.92-3.63 (m, 3H), 3.53-3.39 (m, 2H), 2.26-2.12 
(m, 2H), 2.07-1.73 (m, 5H), 1.67-1.49 (m, 1H); 13C NMR (75 MHz, 
CDCl3): δ 164.3, 161.1, 99.0, 74.2, 57.6, 47.3, 29.7, 22.8, 22.7; 
HRMS (EI): m/z [M]+ for C13H15NO2
•+ calcd. 167.0941; found 
167.0942. 
 
(R)-3-methyl-7,8,9,9a-tetrahydropyrrolo[2,1-c][1,4]oxazepin-5(1H)-
one ((R)-75b): Elution with pure EtOAc provided pure (R)-75b. Yield: 
48.2 mg, 96% (procedure A). [α]D
20 = + 81.8 (c = 0.6, CHCl3). 
 
4-benzyl-7-phenyl-3,4-dihydro-1,4-oxazepin-5(2H)-one (75c): Elu-
tion with heptane/EtOAc (30%) provided pure 75c. Yield: 61.2 mg, 
73% (procedure A); 62.0 mg, 74% (procedure B). 1H NMR (300 MHz, 
CDCl3): δ 7.71-7.60 (m, 2H), 7.45-7.21 (m, 8H), 5.93 (s, 1H), 4.72 (s, 
2H), 4.45-4.33 (m, 2H), 3.63-3.52 (m, 2H); 13C NMR (75 MHz, CDCl3): 
δ 166.7, 159.1, 136.9, 135.5, 130.1, 128.8, 128.4, 128.1, 127.6, 
126.6, 98.8, 71.7, 51.7, 48.2; HRMS (EI): m/z [M]+ for C18H17NO2
•+ 
calcd. 279.1254; found 279.1262. 
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4-benzyl-7-ethyl-3,4-dihydro-1,4-oxazepin-5(2H)-one (75d): Elution 
with heptane/EtOAc (40%) provided pure 75d. Yield: 58.3 mg, 84% 
(procedure A); 59.7 mg, 86% (procedure B). 1H NMR (300 MHz, 
CDCl3): δ 7.40-7.18 (m, 5H), 5.22 (s, 1H), 4.65 (s, 2H), 4.22-4.10 (m, 
2H), 3.50-3.38 (m, 2H), 2.20 (q, J = 7.5 Hz, 2H), 1.11 (t, J = 7.5 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 166.9, 164.9, 137.1, 128.7, 128.1, 
127.5, 97.7, 71.4, 51.5, 48.0, 29.6, 12.1; HRMS (EI): m/z [M]+ for 
C14H17NO2
•+ calcd. 231.1254; found 231.1244. 
 
4-benzyl-7-pentyl-3,4-dihydro-1,4-oxazepin-5(2H)-one (75e): Elu-
tion with heptane/EtOAc (40%) provided pure 75e. Yield: 73.8 mg, 
90% (procedure A); 70.5 mg, 86% (procedure B). 1H NMR (300 MHz, 
CDCl3): δ 7.38-7.18 (m, 5H), 5.22 (s, 1H), 4.65 (s, 2H), 4.22-4.08 (m, 
2H), 3.49-3.37 (m, 2H), 2.23-2.08 (m, 2H), 1.61-1.45 (m, 2H), 1.41-
1.18 (m, 4H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
166.8, 163.8, 137.1, 128.7, 128.1, 127.5, 98.6, 71.4, 51.4, 48.0, 36.5, 
31.2, 27.3, 22.4, 14.0; HRMS (EI): m/z [M]+ for C17H23NO2
•+ calcd. 
273.1723; found 273.1691. 
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N-tert-butyl-2-(7-methyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-
yl)pentanamide (75f): Elution with heptane/EtOAc (50%) provided 
pure 75f. Yield: 75.3 mg, 89% (procedure A); 75.4 mg, 89% (proce-
dure B). 1H NMR (300 MHz, CDCl3): δ 5.99 (bs, 1H), 5.15 (s, 1H), 
4.89 (t, J = 7.7 Hz, 1H), 4.37 (dd, J = 12.4, 6.3 Hz, 1H), 4.06 (dd, J = 
12.4, 6.7 Hz, 1H), 3.68 (dd, J = 15.9, 6.3 Hz, 1H), 3.47 (dd, J = 15.9, 
6.7 Hz, 1H), 1.95 (s, 3H), 1.91-1.71 (m, 1H), 1.65-1.45 (m, 1H), 1.39-
1.17 (m, 11H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
169.8, 167.3, 160.7, 98.6, 72.0, 56.7, 51.2, 43.8, 30.2, 28.7, 22.6, 
19.2, 13.9; HRMS (ESI): m/z [M+H]+ for C15H27N2O3
+ calcd. 283.2016; 
found 283.2020. 
 
N-tert-butyl-2-(7-ethyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-
yl)pentanamide (75g): Elution with heptane/EtOAc (40%) provided 
pure 75g. Yield: 66.7 mg, 75% (procedure A); 56.9 mg, 64% (proce-
dure B). 1H NMR (300 MHz, CDCl3): δ 5.99 (bs, 1H), 5.14 (s, 1H), 
4.90 (t, J = 7.7 Hz, 1H), 4.38 (dd, J = 12.4, 6.3 Hz, 1H), 4.05 (dd, J = 
12.4, 6.6 Hz, 1H), 3.68 (dd, J = 15.9, 6.3 Hz, 1H), 3.46 (dd, J = 15.9, 
6.6 Hz, 1H), 2.21 (q, J = 7.5 Hz, 2H), 1.90-1.71 (m, 1H), 1.65-1.47 (m, 
1H), 1.36-1.19 (m, 11H), 1.12 (t, J = 7.5 Hz, 3H), 0.93 (t, J = 7.3 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 169.8, 167.6, 165.3, 97.1, 71.9, 
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56.7, 51.2, 43.9, 30.2, 29.6, 28.7, 19.2, 13.9, 12.0; HRMS (ESI): m/z 
[M+H]+ for C16H29N2O3
+ calcd. 297.2173; found 297.2175. 
 
N-cyclohexyl-2-(7-ethyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-
yl)pentanamide (75h): Elution with heptane/EtOAc (40%) provided 
pure 75h. Yield: 74.5 mg, 77% (procedure A); 71.6 mg, 74% (proce-
dure B). 1H NMR (300 MHz, CDCl3): δ 6.12 (bd, J = 8.1 Hz, 1H), 5.14 
(s, 1H), 4.98 (dd, J = 8.3, 7.2 Hz, 1H), 4.38 (dd, J = 12.4, 6.3 Hz, 1H), 
4.07 (dd, J = 12.4, 6.6 Hz, 1H), 3.78-3.58 (m, 2H), 3.47 (dd, J = 15.9, 
6.6 Hz, 1H), 2.20 (q, J = 7.5 Hz, 2H), 1.93-1.51 (m, 7H), 1.43-1.01 (m, 
10H), 0.93 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 169.6, 
167.7, 165.4, 97.1, 71.9, 56.3, 48.1, 44.0, 33.0, 32.8, 30.4, 29.6, 25.5, 
24.8, 24.7, 19.2, 13.9, 12.1; HRMS (EI): m/z [M]+ for C18H30N2O3
•+ 
calcd. 322.2251; found 322.2276. 
 
N-benzyl-2-(7-methyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-
yl)pentanamide (75i): Elution with heptane/EtOAc (40%) provided 
pure 75i. Yield: 83.5 mg, 88% (procedure A); 77.8 mg, 82% (proce-
dure B). 1H NMR (300 MHz, CDCl3): δ 7.37-7.18 (m, 5H), 6.94 (t, J = 
5.6 Hz, 1H), 5.12-5.01 (m, 2H), 4.37 (d, J = 6.0 Hz, 2H), 4.26 (dd, J = 
12.4, 6.3 Hz, 1H), 3.95 (dd, J = 12.4, 6.6 Hz, 1H), 3.65 (dd, J = 15.9, 
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6.3 Hz, 1H), 3.47 (dd, J = 15.9, 6.6 Hz, 1H), 1.95-1.76 (m, 4H), 1.71-
1.52 (m, 1H), 1.38-1.18 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 170.6, 167.4, 160.8, 138.3, 128.6, 127.7, 127.4, 98.4, 
71.8, 56.2, 43.9, 43.3, 30.5, 22.6, 19.2, 13.9; HRMS (EI): m/z [M]+ for 
C18H24N2O3
•+ calcd. 316.1781; found 316.1788. 
 
2-(7-methyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-yl)-N-(2,4,4-
trimethylpentan-2-yl)pentanamide (75j): Elution with hep-
tane/EtOAc (30%) provided pure 75j. Yield: 88.3 mg, 87% (procedure 
A); 85.3 mg, 84% (procedure B). 1H NMR (300 MHz, CDCl3): δ 6.01 
(bs, 1H), 5.14 (s, 1H), 4.87 (t, J = 7.7 Hz, 1H), 4.33 (dd, J = 12.4, 6.3 
Hz, 1H), 4.12 (dd, J = 12.4, 6.5 Hz, 1H), 3.64 (dd, J = 15.9, 6.3 Hz, 
1H), 3.49 (dd, J = 15.9, 6.5 Hz, 1H), 1.94 (s, 3H), 1.89-1.70 (m, 2H), 
1.68-1.45 (m, 2H), 1.41-1.14 (m, 8H), 0.98 (s, 9H), 0.92 (t, J = 7.3 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 169.4, 167.2, 160.6, 98.6, 71.9, 
57.0, 55.2, 51.7, 43.8, 31.6, 31.4, 30.2, 29.1, 29.0, 22.6, 19.3, 13.9; 
HRMS (EI): m/z [M]+ for C19H34N2O3
•+ calcd. 338.2564; found 
338.2547. 
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N-tert-butyl-2-(5-oxo-7-phenyl-2,3-dihydro-1,4-oxazepin-4(5H)-
yl)pentanamide (75k): Elution with heptane/EtOAc (40%) provided 
pure 75k. Yield: 92.0 mg, 89% (procedure A); 80.6 mg, 78% (proce-
dure B). 1H NMR (300 MHz, CDCl3): δ 7.71-7.62 (m, 2H), 7.46-7.32 
(m, 3H), 6.06 (bs, 1H), 5.84 (s, 1H), 4.96 (t, J = 7.7 Hz, 1H), 4.62 (dd, 
J = 12.4, 6.3 Hz, 1H), 4.27 (dd, J = 12.4, 6.7 Hz, 1H), 3.82 (dd, J = 
15.9, 6.3 Hz, 1H), 3.60 (dd, J = 15.9, 6.7 Hz, 1H), 1.94-1.75 (m, 1H), 
1.70-1.51 (m, 1H), 1.41-1.21 (m, 11H), 0.95 (t, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3): δ 169.7, 167.3, 159.3, 135.4, 130.1, 128.4, 
126.5, 98.2, 72.3, 56.9, 51.3, 44.1, 30.3, 28.7, 19.3, 13.9; HRMS (EI): 
m/z [M]+ for C20H28N2O3
•+ calcd. 344.2094; found 344.2125. 
 
N-tert-butyl-2-(7-methyl-5-oxo-2,3-dihydro-1,4-oxazepin-4(5H)-yl)-
3-phenylpropanamide (75l): Elution with heptane/EtOAc (50%) pro-
vided pure 75l. Yield: 83.3 mg, 84% (procedure A); 85.2 mg, 86% 
(procedure B). 1H NMR (300 MHz, CDCl3): δ 7.36-7.10 (m, 5H), 5.95 
(bs, 1H), 5.25 (t, J = 8.2 Hz, 1H), 5.08 (s, 1H), 4.12-3.90 (m, 2H), 
3.77-3.62 (m, 1H), 3.55-3.42 (m, 1H), 3.21 (dd, J = 14.4, 7.8 Hz, 1H), 
2.94 (dd, J = 14.4, 8.5 Hz, 1H), 1.89 (s, 3H), 1.26 (s, 9H); 13C NMR 
(75 MHz, CDCl3): δ 169.2, 167.3, 160.8, 136.9, 129.0, 128.6, 126.7, 
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98.4, 71.8, 57.7, 51.2, 44.1, 34.5, 28.6, 22.6; HRMS (EI): m/z [M]+ for 
C19H26N2O3
•+ calcd. 330.1938; found 330.1948. 
 
N-tert-butyl-4-methyl-2-(7-methyl-5-oxo-2,3-dihydro-1,4-oxazepin-
4(5H)-yl)pentanamide (75m): Elution with heptane/EtOAc (50%) 
provided pure 75m. Yield: 84.5 mg, 95% (procedure A); 75.6 mg, 
85% (procedure B). 1H NMR (300 MHz, CDCl3): δ 6.02 (bs, 1H), 5.14 
(s, 1H), 4.98 (dd, J = 8.5, 6.7 Hz, 1H), 4.37 (dd, J = 12.4, 6.3 Hz, 1H), 
4.03 (dd, J = 12.4, 6.6 Hz, 1H), 3.67 (dd, J = 15.9, 6.3 Hz, 1H), 3.45 
(dd, J = 15.9, 6.6 Hz, 1H), 1.94 (s, 3H), 1.70-1.35 (m, 3H), 1.30 (s, 
9H), 0.92 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 169.8, 167.2, 160.6, 98.6, 71.9, 55.1, 51.1, 43.8, 
36.8, 28.6, 25.0, 23.1, 22.5, 22.2; HRMS (ESI): m/z [M+H]+ for 
C16H29N2O3
+ calcd. 297.2173; found 297.2180. 
 
N-tert-butyl-4-butyl-7-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-
oxazepine-3-carboxamide (75n): Elution with heptane/EtOAc (50%) 
provided pure 75n. Yield: 69.5 mg, 82% (procedure A); 75.4 mg, 89% 
(procedure B). 1H NMR (300 MHz, CDCl3): δ 5.86 (bs, 1H), 5.17 (s, 
1H), 5.01 (dd, J = 12.0, 5.4 Hz, 1H), 4.06 (d, J = 5.4 Hz, 1H), 3.98 (d, 
J = 12.0 Hz, 1H), 3.69-3.52 (m, 1H), 3.31-3.16 (m, 1H), 1.92 (s, 3H), 
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1.65-1.20 (m, 13H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 166.3, 165.5, 162.6, 99.2, 71.5, 64.6, 51.7, 49.3, 29.6, 28.6, 
21.9, 20.2, 13.8; HRMS (ESI): m/z [M+H]+ for C15H27N2O3
+ calcd. 
283.2016; found 283.2019. 
 
N-tert-butyl-4-(4-methoxybenzyl)-7-methyl-5-oxo-2,3,4,5-
tetrahydro-1,4-oxazepine-3-carboxamide (75o): Elution with hep-
tane/EtOAc (50%) provided pure 75o. Yield: 85.2 mg, 82% (proce-
dure A); 82.1 mg, 79% (procedure B). 1H NMR (300 MHz, CDCl3): δ 
7.24 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.62 (bs, 1H), 5.23 
(s, 1H), 4.92 (dd, J = 12.0, 5.4 Hz, 1H), 4.66 (d, J = 14.3 Hz, 1H), 4.54 
(d, J = 14.3 Hz, 1H), 4.08 (d, J = 5.4 Hz, 1H), 3.85 (d, J = 12.0 Hz, 
1H), 3.79 (s, 3H), 1.91 (s, 3H), 1.18 (s, 9H); 13C NMR (75 MHz, 
CDCl3): δ 165.8, 165.7, 162.9, 159.5, 130.2, 128.6, 114.4, 98.9, 71.6, 
63.5, 55.3, 51.9, 51.5, 28.3, 22.0; HRMS (ESI): m/z [M+H]+ for 
C19H27N2O4
+ calcd. 347.1965; found 347.1966. 
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Chapter 4 
Synthesis of starting materials 
 
2-Bromophenylacetaldehyde (110)54f and 3-phenylpropargylamine 
(111b)76 were synthesized following known procedures. 
 
4-(4-Chlorophenyl)-2-methylbut-3-yn-2-amine (111a). 1-Chloro-4-
iodobenzene (0.715 g, 3 mmol) was placed in a screw cap vial and 
dissolved in THF (5 mL) followed by addition of 2-methylbut-3-yn-2-
amine (0.299 g, 3.6 mmol), Pd(PPh3)2Cl2 (63 mg, 0.09 mmol), CuI (29 
mg, 0.15 mmol) and triethylamine (1 mL). The vial was several times 
evacuated and backfilled with argon. The sealed reaction mixture was 
heated with a stirring at 80 °C for 18.5 h. The resulting mixture was 
diluted with EtOAc (30 mL). The solids were filtered off and the filtrate 
was evaporated with silica followed by column chromatography with 
EtOAc-MeOH (1-3%) as eluent delivering pure product. Yield: 230 
mg, 40%. 1H NMR (300 MHz, CDCl3): δ 7.30 (d, J = 8.3 Hz, 2H), 7.24 
(d, J = 8.3 Hz, 2H), 1.80 (bs, 2H), 1.48 (s, 6H); 13C NMR (75 MHz, 
CDCl3): δ 133.8, 132.7, 128.5, 121.9, 79.0, 45.8, 31.8. 
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Synthesis of propargylamides 102a-g,i through the Ugi reaction  
3-Substituted propiolic acid 39 (0.5 mmol) was dissolved in methanol 
(2 mL) followed by addition of appropriate 2-bromophenethylamine 96 
(0.5 mmol), aldehyde 2 (0.5 mmol) and isocyanide 4 (0.5 mmol). The 
reaction mixture was stirred at rt for 24 h in a sealed screw cap vial. 
The resulting mixture was concentrated and subjected to the column 
chromatography on silicagel with heptane-EtOAc (15-40%) as eluent 
to give the desired propargylamides 102a-g,i. 
 
N-benzyl-2-(N-(2-bromophenethyl)but-2-ynamido)pentanamide 
(102a). Mixture of rotamers ~ 4:1.75 Yield: 200 mg, 88%. 1H NMR 
(300 MHz, CDCl3): δ 7.60-7.42 (m, 1H), 7.39-6.97 (m, 9H), 5.03-4.74 
(m, 1H), 4.58-4.28 (m, 2H), 4.02-3.80 (m, 0.8H), 3.74-3.48 (m, 1H), 
3.38-3.19 (m, 0.2H), 3.17-2.85 (m, 2H), 2.34-1.55 (m, 5H), 1.49-1.12 
(m, 2H), 1.06-0.80 (m, 3H); 13C NMR (CDCl3, 75 MHz, major 
rotamer): δ 170.4, 156.1, 138.2, 138.0, 132.8, 131.2, 128.6, 128.4, 
127.8, 127.7, 127.3, 124.5, 90.3, 73.4, 57.3, 46.4, 43.5, 36.3, 30.4, 
19.4, 13.9, 4.4; HRMS (EI, [M]+) for C24H27BrN2O2
•+ calcd. 454.1250, 
found 454.1239. 
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N-(2-bromophenethyl)-N-(1-(4-cyanophenyl)-2-oxo-2-(2,4,4-
trimethylpentan-2-ylamino)ethyl)but-2-ynamide (102b). Mixture of 
rotamers ~ 17:3.75 Yield: 244 mg, 91%. 1H NMR (300 MHz, CDCl3): δ 
7.74-7.33 (m, 5H), 7.26-6.95 (m, 3H), 6.33 (s, 0.85H), 6.11 (s, 0.15H), 
5.92 (s, 0.85H), 5.77 (s, 0.15H), 3.94-3.73 (m, 1.7H), 3.73-3.57 (m, 
0.15H), 3.44-3.24 (m, 0.15H), 3.09-2.67 (m, 1.85H), 2.56-2.38 (m, 
0.15H), 2.04 (s, 3H), 1.77 (s, 0.3H), 1.72 (s, 1.7H), 1.47 (s, 0.9H), 
1.44 (s, 5.1H), 1.01 (s, 1.35H), 0.95 (s, 7.65H); 13C NMR (75 MHz, 
CDCl3, major rotamer): δ 166.8, 155.8, 140.5, 137.7, 132.8, 132.5, 
131.0, 129.8, 128.5, 127.8, 124.3, 118.4, 112.3, 91.0, 73.2, 61.9, 
56.0, 52.1, 48.0, 36.4, 31.6, 31.4, 28.7, 28.6, 4.5; MS (CI): m/z 
(relative intensity) 536 ([M+H]+, 100), 407 (52), 380 (24). 
 
N-(2-bromo-4,5-dimethoxyphenethyl)-N-(2-(tert-butylamino)-2-
oxo-1-phenylethyl)but-2-ynamide (102c). Mixture of rotamers ~ 
17:3.75 Yield: 239 mg, 93%. 1H NMR (300 MHz, CDCl3): δ 7.59-7.30 
(m, 5H), 6.88 (s, 0.85H), 6.83 (s, 0.15H), 6.51 (s, 0.15H), 6.29 (s, 
0.85H), 6.05 (s, 0.15H), 6.00-5.82 (m, 1.7H), 5.61 (bs, 0.15H), 3.92-
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3.52 (m, 7.85H), 3.38-3.19 (m, 0.15H), 3.01-2.76 (m, 1H), 2.47-2.19 
(m, 1H), 2.06 (s, 0.45H), 2.01 (s, 2.55H), 1.40 (s, 1.35H), 1.35 (s, 
7.65H); 13C NMR (75 MHz, CDCl3, major rotamer): δ 168.3, 155.7, 
148.3, 148.1, 135.1, 130.2, 129.8, 128.9, 128.6, 115.2, 113.8, 113.6, 
89.5, 73.6, 61.8, 56.1, 56.0, 51.7, 47.3, 36.1, 28.6, 4.5; HRMS (EI, 
[M]+) for C26H31BrN2O4
•+ calcd. 514.1462, found 514.1457. 
 
N-(2-bromophenethyl)-N-(1-(cyclohexylamino)-4-methyl-1-
oxopentan-2-yl)pent-2-ynamide (102d). Mixture of rotamers ~ 4:1.75 
Yield: 220 mg, 93%. 1H NMR (300 MHz, CDCl3): δ 7.58-7.47 (m, 1H), 
7.39-7.18 (m, 2H), 7.16-7.01 (m, 1H), 6.58 (bd, J = 8.0 Hz, 0.8H), 
5.90 (bd, J = 8.0 Hz, 0.2H), 5.08-4.73 (m, 1H), 4.03-3.84 (m, 0.8H), 
3.84-3.47 (m, 2H), 3.42-3.24 (m, 0.2H), 3.20-2.84 (m, 2H), 2.50-2.30 
(m, 2H), 2.03-0.72 (m, 22H); 13C NMR (75 MHz, CDCl3, major 
rotamer): δ 169.6, 156.1, 138.0, 132.8, 131.1, 128.4, 127.7, 124.4, 
95.3, 73.4, 55.4, 48.2, 46.3, 36.7, 36.2, 32.7, 32.6, 25.5, 24.8, 24.7, 
24.6, 22.8, 22.4, 12.9, 12.7; HRMS (EI, [M]+) for C25H35BrN2O2
•+ calcd. 
474.1876, found 474.1871. 
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N-(2-bromophenethyl)-N-(4-methyl-1-(naphthalen-2-ylamino)-1-
oxopentan-2-yl)non-2-ynamide (102e). Mixture of rotamers ~ 9:1.75 
Yield: 247 mg, 86%. 1H NMR (300 MHz, CDCl3): δ 9.37 (bs, 0.9H), 
8.78 (bs, 0.1H), 8.37-8.26 (m, 1H), 7.84-6.93 (m, 10H), 5.29-5.21 (m, 
0.1H), 5.20-5.01 (m, 0.9H), 4.14-3.94 (m, 0.9H), 3.83-3.63 (m, 1H), 
3.54-3.35 (m, 0.1H), 3.30-2.90 (m, 2H), 2.40-0.65 (m, 22H); 13C NMR 
(75 MHz, CDCl3, major rotamer): δ 169.2, 156.8, 137.6, 135.6, 133.8, 
132.8, 131.2, 130.6, 128.6, 128.4, 127.68, 127.66, 127.5, 126.4, 
124.9, 124.5, 120.1, 116.5, 95.4, 73.7, 56.9, 46.6, 36.7, 36.1, 31.2, 
28.7, 27.6, 24.9, 22.69, 22.66, 22.4, 19.3, 14.0; HRMS (EI, [M]+) for 
C33H39BrN2O2
•+ calcd. 574.2189, found 574.2217. 
 
2-(N-(2-bromo-4,5-dimethoxyphenethyl)-3-phenylpropiolamido)-
N-tert-butylpentanamide (102f). Mixture of rotamers ~ 4:1.75 Yield: 
217 mg, 80%. 1H NMR (300 MHz, CDCl3): δ 7.62-7.52 (m, 2H), 7.49-
7.32 (m, 3H), 6.99 (s, 0.2H), 6.94 (s, 0.8H), 6.90 (s, 0.2H), 6.72 (s, 
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0.8H), 6.34 (bs, 0.8H), 5.62 (bs, 0.2H), 4.80 (t, J = 7.6 Hz, 1H), 4.08-
3.33 (m, 8H), 3.20-2.78 (m, 2H), 2.23-1.96 (m, 1H), 1.90-1.64 (m, 
1H), 1.48-1.18 (m, 11H), 1.06-0.92 (m, 3H); 13C NMR (75 MHz, 
CDCl3, major rotamer): δ 169.5, 155.9, 148.6, 148.4, 132.4, 130.3, 
129.9, 128.6, 120.3, 115.5, 114.2, 113.4, 91.0, 81.8, 57.7, 56.1, 55.8, 
51.3, 46.5, 36.5, 30.2, 28.6, 19.4, 13.9; HRMS (EI, [M]+) for 
C28H35BrN2O4
•+ calcd. 542.1775, found 542.1796. 
 
N-(2-bromophenethyl)-N-(1-(tert-butylamino)-1-oxo-3-
phenylpropan-2-yl)-3-(4-methoxyphenyl)propiolamide (102g). 
Mixture of rotamers ~ 21:4.75 Yield: 121 mg, 43%. 1H NMR (300 MHz, 
CDCl3): δ 7.60-6.98 (m, 11H), 6.95-6.78 (m, 2H), 6.46 (bs, 0.84H), 
5.61 (bs, 0.16H), 5.11-4.81 (m, 1H), 4.02-2.84 (m, 9H), 1.32 (s, 
7.56H), 1.29 (s, 1.44H); 13C NMR (75 MHz, CDCl3, major rotamer): δ 
169.0, 161.2, 156.3, 138.0, 137.0, 134.4, 132.9, 131.1, 129.1, 128.6, 
128.4, 127.7, 126.7, 124.5, 114.2, 112.0, 91.9, 80.9, 60.2, 55.4, 51.3, 
47.4, 36.4, 34.3, 28.5; HRMS (ESI, [M+H]+) for C31H34BrN2O3
+ calcd. 
561.1747, found 561.1756. 
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N-(1-(benzo[b]thiophen-3-yl)-2-(tert-butylamino)-2-oxoethyl)-N-(2-
bromo-4,5-dimethoxyphenethyl)but-2-ynamide (102i). Mixture of 
rotamers ~ 9:1.75 Yield: 203 mg, 71%. 1H NMR (300 MHz, CDCl3): δ 
8.01 (s, 0.9H), 7.94-7.83 (m, 1H), 7.80-7.61 (m, 1.1H), 7.47-7.30 (m, 
2H), 6.82 (s, 0.9H), 6.70 (s, 0.1H), 6.40 (s, 1H), 6.32 (s, 0.1H), 6.16 
(s, 0.9H), 6.07 (bs, 0.9H), 5.65 (bs, 0.1H), 3.87-3.56 (m, 7.9H), 3.46-
3.30 (m, 0.1H), 2.93-2.63 (m, 1H), 2.18-1.89 (m, 4H), 1.41 (s, 0.9H), 
1.38 (s, 8.1H); 13C NMR (75 MHz, CDCl3, major rotamer): δ 168.0, 
155.8, 148.3, 148.1, 139.5, 138.5, 130.1, 129.5, 128.0, 125.2, 125.0, 
122.9, 121.6, 115.2, 113.7, 113.4, 90.0, 73.5, 56.1, 54.4, 51.8, 46.7, 
36.1, 28.6, 4.6; HRMS (EI, [M]+) for C28H31BrN2O4S
•+ calcd. 570.1182, 
found 570.1207. 
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Synthesis of 1-(N-(2-bromophenethyl)but-2-ynamido)-N-
cyclohexylcycloheptanecarbox-amide (102h) through the Ugi re-
action  
 
Tetrolic acid (39a) (42 mg, 0.5 mmol) was dissolved in methanol (2 
mL) followed by addition of 2-bromophenethylamine (96a) (100 mg, 
0.5 mmol), cycloheptanone (109) (56 mg, 0.5 mmol) and cyclohexyl 
isocyanide (4b) (55 mg, 0.5 mmol). The reaction mixture was stirred 
at rt for 2 h and then heated at 70 °C for 72 h in a sealed screw cap 
vial. The resulting mixture was concentrated and subjected to the col-
umn chromatography on silicagel with heptane-EtOAc (40%) as elu-
ent to give the desired propargylamide 102h. Mixture of rotamers ~ 
3:1.75 Yield: 85 mg, 35%. 1H NMR (300 MHz, CDCl3): δ 7.61-7.48 (m, 
1H), 7.33-7.19 (m, 2H), 7.18-7.03 (m, 1H), 5.96-5.59 (m, 1H), 3.96-
3.63 (m, 2.5H), 3.62-3.50 (m, 0.5H), 3.28-3.10 (m, 1.5H), 3.03-2.93 
(m, 0.5H), 2.49-2.31 (m, 1.5H), 2.21-1.01 (m, 23.5H); 13C NMR (75 
MHz, CDCl3): δ 173.5, 155.9, 153.5, 138.4, 137.9, 133.0, 131.0, 
130.9, 128.5, 128.4, 127.9, 127.7, 124.6, 124.3, 88.2, 83.3, 75.0, 
69.3, 48.4, 46.6, 39.4, 38.4, 35.5, 35.2, 32.9, 30.0, 25.7, 24.8, 23.6, 
4.3, 3.7; HRMS (ESI, [M+Na]+) for C26H35BrN2O2Na
+ calcd. 509.1774, 
found 509.1778. 
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Synthesis of N-(1-(benzo[b]thiophen-3-yl)-2-(tert-butylamino)-2-
oxoethyl)-N-(2-iodo-4,5-dimet-hoxyphenethyl)but-2-ynamide 
(102i') through the Ugi reaction  
 
Tetrolic acid (39a) (42 mg, 0.5 mmol) was dissolved in methanol (2 
mL) followed by addition of 2-iodo-4,5-dimethoxyphenethylamine 
(96b’) (154 mg, 0.5 mmol), benzothiophene-3-carbaldehyde (2f) (81 
mg, 0.5 mmol) and tert-butyl isocianide (4a) (42 mg, 0.5 mmol). The 
reaction mixture was stirred at rt for 48 h in a sealed screw cap vial. 
The resulting mixture was concentrated and subjected to the column 
chromatography on silicagel with heptane-EtOAc (15-25%) as eluent 
to give the desired propargylamide 102i'. Mixture of rotamers ~ 9:1.75 
Yield: 142 mg, 46%. 1H NMR (300 MHz, CDCl3): δ 8.02 (s, 0.9H), 
7.93-7.82 (m, 1H), 7.80-7.62 (m, 1.1H), 7.46-7.31 (m, 2H), 7.03 (s, 
0.9H), 6.91 (s, 0.1H), 6.42 (s, 0.1H), 6.38 (s, 0.9H), 6.31 (s, 0.1H), 
6.23 (s, 0.9H), 6.06 (bs, 0.9H), 5.65 (bs, 0.1H), 3.92-3.49 (m, 7.9H), 
3.45-3.28 (m, 0.1H), 2.90-2.65 (m, 1H), 2.29-2.08 (m, 1.3H), 2.03 (s, 
2.7H), 1.41 (s, 0.9H), 1.38 (s, 8.1H); 13C NMR (75 MHz, CDCl3, major 
rotamer): δ 168.0, 155.8, 149.3, 148.0, 139.6, 138.5, 134.2, 129.3, 
128.1, 125.2, 125.0, 123.0, 121.6, 121.4, 112.7, 90.3, 87.3, 73.7, 
56.1, 56.0, 54.6, 51.8, 46.9, 40.3, 28.6, 5.0; HRMS (EI, [M]+) for 
C28H31IN2O4S
•+ calcd. 618.1044, found 618.1040. 
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Synthesis of propargylamides 102j-l through the Ugi reaction  
3-Substituted propiolic acid 39 (0.5 mmol) was dissolved in methanol 
(2 mL) followed by addition of amine 3 (0.5 mmol), 2-
bromophenylacetaldehyde (110) (100 mg, 0.5 mmol) and isocyanide 
4 (0.5 mmol). The reaction mixture was stirred at rt for 24 h in a 
sealed screw cap vial. The resulting mixture was concentrated and 
subjected to the column chromatography on silicagel with heptane-
EtOAc (10-30%) as eluent to give the desired propargylamides 102j-l. 
 
N-benzyl-N-(3-(2-bromophenyl)-1-(cyclohexylamino)-1-
oxopropan-2-yl)but-2-ynamide (102j). Mixture of rotamers ~ 7:3.75 
Yield: 151 mg, 63%. 1H NMR (300 MHz, CDCl3): δ 7.63-7.43 (m, 1H), 
7.41-6.98 (m, 8H), 5.85 (bd, J = 6.9 Hz, 0.7H), 5.30-5.08 (m, 0.3H), 
5.07-4.77 (m, 1.3H), 4.76-4.59 (m, 0.7H), 4.23 (d, J = 15.7 Hz, 0.7H), 
3.80-3.12 (m, 3.3H), 1.98 (s, 3H), 1.82-0.68 (m, 10H); 13C NMR (75 
MHz, CDCl3): δ 167.7, 167.5, 155.5, 155.0, 137.3, 137.0, 136.8, 
136.7, 132.8, 132.7, 132.3, 131.9, 129.0, 128.9, 128.8, 128.7, 128.4, 
128.0, 127.79, 127.76, 127.5, 124.7, 124.6, 91.3, 90.5, 73.6, 73.4, 
61.0, 58.7, 52.8, 48.4, 48.0, 36.1, 34.6, 32.54, 32.49, 32.3, 32.2, 25.5, 
25.4, 24.56, 24.54, 24.49, 4.2, 4.1; HRMS (EI, [M]+) for 
C26H29BrN2O2
•+ calcd. 480.1407, found 480.1421. 
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N-(3-(2-bromophenyl)-1-(4-methoxyphenylamino)-1-oxopropan-2-
yl)-N-cyclopropylpent-2-ynamide (102k). Yield: 164 mg, 70%. 1H 
NMR (300 MHz, CDCl3): δ 8.71 (s, 1H), 7.62-7.48 (m, 1H), 7.39 (d, J 
= 8.8 Hz, 2H), 7.34-7.18 (m, 2H), 7.16-7.03 (m, 1H), 6.82 (d, J = 8.8 
Hz, 2H), 5.09 (t, J = 7.4 Hz, 1H), 3.76 (s, 3H), 3.68-3.50 (m, 2H), 
2.63-2.47 (m, 1H), 2.45-2.29 (m, 2H), 1.19 (t, J = 7.4 Hz, 3H), 1.09-
0.74 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 168.1, 158.9, 156.3, 
136.9, 133.0, 131.3, 131.1, 128.6, 127.6, 124.9, 121.6, 114.0, 97.6, 
74.3, 61.4, 55.5, 34.0, 30.4, 12.84, 12.81, 10.5, 8.3; HRMS (EI, [M]+) 
for C24H25BrN2O3
•+ calcd. 468.1043, found 468.1041. 
 
N-(3-(2-bromophenyl)-1-(tert-butylamino)-1-oxopropan-2-yl)-N-
pentyl-3-phenylpropiolamide (102l). Mixture of rotamers ~ 4:1.75 
Yield: 165 mg, 66%. 1H NMR (300 MHz, CDCl3): δ 7.60-7.14 (m, 8H), 
7.14-6.97 (m, 1H), 6.53 (bs, 0.8H), 5.70 (bs, 0.2H), 5.10-4.82 (m, 1H), 
3.72-3.04 (m, 4H), 1.82-1.03 (m, 15H), 1.00-0.71 (m, 3H); 13C NMR 
(75 MHz, CDCl3, major rotamer): δ 168.6, 155.8, 136.6, 132.9, 132.4, 
131.3, 130.3, 128.6, 128.4, 127.5, 124.9, 120.3, 90.8, 81.7, 58.9, 
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51.3, 48.4, 34.4, 29.3, 29.1, 28.5, 22.3, 14.0; HRMS (EI, [M]+) for 
C27H33BrN2O2
•+ calcd. 496.1720, found 496.1703. 
Synthesis of N-(3-(2-bromophenyl)-1-(tert-butylamino)-1-
oxopropan-2-yl)-N-(4-(4-chlorophe-nyl)-2-methylbut-3-yn-2-
yl)benzamide (102m) through the Ugi reaction  
 
Benzoic acid (1a) (61 mg, 0.5 mmol) was dissolved in methanol (2 
mL) followed by addition of 4-(4-chlorophenyl)-2-methylbut-3-yn-2-
amine (111a) (97 mg, 0.5 mmol), 2-bromophenylacetaldehyde (110) 
(100 mg, 0.5 mmol) and tert-butyl isocianide (4a) (42 mg, 0.5 mmol). 
The reaction mixture was stirred at rt for 24 h in a sealed screw cap 
vial. The resulting mixture was concentrated and subjected to the col-
umn chromatography on silicagel with heptane-EtOAc (10%) as elu-
ent to give the desired propargylamide 102m. Yield: 161 mg, 56%. 1H 
NMR (300 MHz, CDCl3): δ 7.50-7.02 (m, 12H), 6.90 (bs, 2H), 4.74 
(dd, J = 2.9, 8.9 Hz, 1H), 4.15-3.69 (m, 1H), 3.68-3.33 (m, 1H), 1.92 
(bs, 6H), 1.37 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 173.6, 137.8, 
134.4, 133.3, 132.7, 132.1, 129.6, 128.5, 128.4, 128.2, 127.4, 126.1, 
125.1, 121.0, 92.8, 86.0, 65.0, 56.3, 51.4, 35.8, 30.3, 30.0, 28.8; 
HRMS (EI, [M]+) for C31H32BrClN2O2
•+ calcd. 578.1330, found 
578.1321. 
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Synthesis of 2-(2-(2-bromophenyl)-N-(3-phenylprop-2-
ynyl)acetamido)-N-tert-butylpentan-amide (102n) through the Ugi 
reaction  
 
2-Bromophenylacetic acid (112) (108 mg, 0.5 mmol) was dissolved in 
methanol (2 mL) followed by addition of 3-phenylpropargylamine 
(111b) (66 mg, 0.5 mmol), butyraldehyde (2b) (36 mg, 0.5 mmol) and 
tert-butyl isocianide (4a) (42 mg, 0.5 mmol). The reaction mixture was 
stirred at rt for 24 h in a sealed screw cap vial. The resulting mixture 
was concentrated and subjected to the column chromatography on 
silicagel with heptane-EtOAc (10%) as eluent. The fractions contain-
ing 102n (determined by MS) were evaporated and transferred to the 
next reductive Heck cyclization step. Crude yield: 125 mg, 52%. 
HRMS (EI, [M]+) for C26H31BrN2O2
•+ calcd. 482.1563, found 482.1568. 
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Synthesis of 2-(2-bromophenyl)-N-(2-(tert-butylamino)-1-(4-
fluorophenyl)-2-oxoethyl)-N-(3-(4-chlorophenyl)prop-2-
ynyl)acetamide (102o) through the Ugi reaction  
 
2-Bromophenylacetic acid (112) (108 mg, 0.5 mmol) was dissolved in 
methanol (2 mL) followed by addition of 4-(4-chlorophenyl)-2-
methylbut-3-yn-2-amine (111a) (97 mg, 0.5 mmol), 4-fluoro-
benzaldehyde (2g) (62 mg, 0.5 mmol) and tert-butyl isocianide (4a) 
(42 mg, 0.5 mmol). The reaction mixture was stirred at rt for 24 h in a 
sealed screw cap vial. The resulting mixture was concentrated and 
subjected to the column chromatography on silicagel with heptane-
EtOAc (10%) as eluent to give the desired propargylamide 102o. 
Yield: 99 mg, 33%. 1H NMR (300 MHz, CDCl3): δ 7.63-6.90 (m, 12H), 
5.95 (bs, 1H), 5.56 (bs, 1H), 4.33-3.45 (m, 2H), 2.00 (s, 3H), 1.88 (s, 
3H), 1.31 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 172.5, 168.5, 162.1 
(d, J = 247.5 Hz), 135.7, 134.7, 132.7, 132.5, 131.2, 130.1 (d, J = 7.9 
Hz), 128.6, 128.4, 127.4, 125.1, 120.6, 115.6 (d, J = 21.5 Hz), 93.5, 
84.6, 65.6, 57.0, 51.7, 44.5, 30.0, 29.5, 28.5; HRMS (EI, [M]+) for 
C31H31BrClFN2O2
•+ calcd. 596.1236, found 596.1270. 
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General procedure for the reductive Heck cyclization of propar-
gylamides 102 into benzazepines 103-106 
Propargylamide 102 (0.3 mmol) was placed into microwave vial and 
dissolved in DMF (3.3 mL) followed by addition of Pd(PPh3)4 (10.4 
mg, 0.009 mmol), HCOONa (30.6 mg, 0.45 mmol) and distilled water 
(1.1 mL). The vial was several times evacuated and backfilled with 
argon. When the reaction vial was sealed and irradiated under stirring 
at the set temperature of 110 °C for 15 min utilizing maximum power 
of 100 W. Upon completion of the reaction the vial was cooled with a 
stream of air. The reaction mixture was diluted with EtOAc (50 mL), 
washed with water (2×50 mL), dried over Na2SO4 and concentrated 
under reduced pressure. The crude product was subjected to column 
chromatography on silica gel with heptane–EtOAc (7-50%) as eluent. 
 
(Z)-N-benzyl-2-(1-ethylidene-2-oxo-4,5-dihydro-1H-
benzo[d]azepin-3(2H)-yl)pentanamide (103a). Yield: 102 mg, 90%. 
Yellow solid; m.p. 109-111°C; 1H NMR (300 MHz, CDCl3): δ 7.33-7.05 
(m, 8H), 7.04-6.88 (m, 2H), 5.91 (q, J = 7.0 Hz, 1H), 5.05 (t, J = 7.7 
Hz, 1H), 4.46 (dd, J = 6.4, 14.9 Hz, 1H), 4.26 (dd, J = 5.2, 14.9 Hz, 
1H), 3.96-3.60 (m, 2H), 3.11-2.82 (m, 2H), 2.07-1.89 (m, 1H), 1.88-
1.63 (m, 4H), 1.43-1.18 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 171.8, 170.7, 139.5, 138.0, 134.8, 130.9, 130.1, 
129.6, 128.5, 127.7, 127.2, 126.5, 55.2, 43.2, 41.0, 33.5, 30.2, 19.2, 
15.5, 13.9; IR (ATR): ν = 3284, 2958, 1633, 1527, 1456, 1414, 1228, 
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1169, 917, 745, 698, 609, 434; HRMS (EI, [M]+) for C24H28N2O2
•+ 
calcd. 376.2145, found 376.2135. 
 
(Z)-2-(4-cyanophenyl)-2-(1-ethylidene-2-oxo-4,5-dihydro-1H-
benzo[d]azepin-3(2H)-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide 
(103b). Yield: 108 mg, 79%. Yellow solid; m.p. 197-200°C; 1H NMR 
(300 MHz, CDCl3): δ 7.61 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 
7.25-7.12 (m, 3H), 7.05-6.91 (m, 1H), 6.44 (bs, 1H), 6.32 (s, 1H), 5.99 
(q, J = 7.0 Hz, 1H), 3.96-3.68 (m, 2H), 3.15-2.88 (m, 1H), 2.68-2.38 
(m, 1H), 1.89 (d, J = 7.0 Hz, 3H), 1.80 (d, J = 14.9 Hz, 1H), 1.63 (d, J 
= 14.9 Hz, 1H), 1.39 (s, 3H), 1.37 (s, 3H), 0.89 (s, 9H); 13C NMR (75 
MHz, CDCl3): δ 171.7, 167.4, 141.2, 139.1, 134.9, 134.6, 132.4, 
131.6, 130.0, 129.7, 129.5, 127.9, 126.6, 118.4, 112.1, 59.2, 55.8, 
51.6, 42.9, 33.3, 31.6, 31.4, 28.83, 28.76, 15.7; IR (ATR): ν = 3305, 
2923, 1686, 1617, 1556, 1471, 1362, 1170, 738, 559; HRMS (EI, 
[M]+) for C29H35N3O2
•+ calcd. 457.2724, found 457.2731. 
 
(Z)-N-tert-butyl-2-(1-ethylidene-7,8-dimethoxy-2-oxo-4,5-dihydro-
1H-benzo[d]azepin-3(2H)-yl)-2-phenylacetamide (103c). Scale: 
0.45 mmol. The material obtained after column chromatography was 
additionally purified by washing with diethyl ether. Yield: 149 mg, 
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76%. Pale yellow solid; m.p. 194-197°C; 1H NMR (300 MHz, CDCl3): 
δ 7.52-7.31 (m, 5H), 6.74 (s, 1H), 6.41 (s, 1H), 6.19 (s, 1H), 5.94 (q, J 
= 7.0 Hz, 1H), 5.80 (bs, 1H), 3.92-3.74 (m, 7H), 3.74-3.60 (m, 1H), 
3.03-2.71 (m, 1H), 2.51-2.22 (m, 1H), 1.94 (d, J = 7 Hz, 3H), 1.36 (s, 
9H); 13C NMR (75 MHz, CDCl3): δ 171.7, 168.7, 148.6, 147.3, 139.3, 
135.8, 130.2, 129.1, 128.8, 128.3, 127.5, 127.1, 112.4, 59.8, 55.9, 
55.8, 51.7, 42.7, 33.1, 28.6, 15.6; IR (ATR): ν = 3298, 2929, 1681, 
1621, 1539, 1503, 1458, 1258, 1220, 1026, 925, 708, 565; HRMS (EI, 
[M]+) for C26H32N2O4
•+ calcd. 436.2357, found 436.2362. 
 
(Z)-N-cyclohexyl-4-methyl-2-(2-oxo-1-propylidene-4,5-dihydro-
1H-benzo[d]azepin-3(2H)-yl)pentanamide (103d). Yield: 92 mg, 
77%. Yellow amorphous solid; 1H NMR (300 MHz, CDCl3): δ 7.33-
7.11 (m, 3H), 7.10-6.98 (m, 1H), 6.21 (bd, J = 7.8 Hz, 1H), 5.87 (t, J = 
7.6 Hz, 1H), 5.07 (t, J = 7.7 Hz, 1H), 3.93-3.57 (m, 3H), 3.21-2.87 (m, 
2H), 2.28 (pentet, J = 7.5 Hz, 2H), 1.93-0.76 (m, 22H); 13C NMR (75 
MHz, CDCl3): δ 171.9, 169.9, 138.3, 137.5, 134.9, 134.8, 129.9, 
129.7, 127.8, 126.5, 53.7, 47.9, 41.0, 36.5, 33.5, 32.7, 32.4, 25.4, 
24.9, 24.6, 24.5, 23.3, 23.0, 22.3, 13.8; IR (ATR): ν = 3299, 2925, 
2853, 1668, 1619, 1543, 1466, 893, 764, 735, 449; HRMS (EI, [M]+) 
for C25H36N2O2
•+ calcd. 396.2771, found 396.2785. 
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(Z)-2-(1-heptylidene-2-oxo-4,5-dihydro-1H-benzo[d]azepin-3(2H)-
yl)-4-methyl-N-(naphthalen-2-yl)pentanamide (103e). Scale: 0.2 
mmol. Yield: 80 mg, 81%. Brownish solid; m.p. 173-175°C; 1H NMR 
(300 MHz, CDCl3): δ 9.02 (d, J = 3.2 Hz, 1H), 8.18 (s, 1H), 7.82-7.61 
(m, 3H), 7.50-7.30 (m, 3H), 7.28-7.09 (m, 3H), 7.07-6.93 (m, 1H), 
5.89 (t, J = 7.6 Hz, 1H), 5.38 (t, J = 7.4 Hz, 1H), 3.97-3.73 (m, 2H), 
3.21-2.94 (m, 2H), 2.27 (q, J = 7.4 Hz, 2H), 2.07-1.91 (m, 1H), 1.85-
1.69 (m, 1H), 1.69-1.51 (m, 1H), 1.47-1.30 (m, 2H), 1.28-1.07 (m, 
5H), 1.05-0.71 (m, 10H); 13C NMR (75 MHz, CDCl3): δ 172.4, 169.4, 
138.4, 137.4, 135.5, 134.84, 134.79, 133.8, 130.6, 130.1, 129.8, 
128.6, 127.9, 127.7, 127.5, 126.7, 126.4, 124.9, 120.1, 116.7, 54.9, 
41.3, 36.9, 33.7, 31.6, 30.2, 29.3, 29.2, 25.0, 22.9, 22.64, 22.57, 14.0; 
IR (ATR): ν = 3264, 2922, 2853, 1690, 1609, 1555, 1469, 1416, 1351, 
1221, 1183, 810, 742, 472; HRMS (EI, [M]+) for C33H40N2O2
•+ calcd. 
496.3084, found 496.3098. 
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(Z)-2-(1-benzylidene-7,8-dimethoxy-2-oxo-4,5-dihydro-1H-
benzo[d]azepin-3(2H)-yl)-N-tert-butylpentanamide (103f). Scale: 
0.4 mmol. Yield: 162 mg, 87%. Pale yellow amorphous solid; 1H NMR 
(300 MHz, CDCl3): δ 7.54-7.44 (m, 2H), 7.38-7.22 (m, 3H), 6.92 (s, 
1H), 6.65 (s, 1H), 6.56 (s, 1H), 6.16 (bs, 1H), 4.93 (t, J = 7.6 Hz, 1H), 
4.12-3.65 (m, 8H), 3.25-2.78 (m, 2H), 2.10-1.61 (m, 2H), 1.40-1.23 
(m, 2H), 1.18 (bs, 9H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 172.0, 169.9, 149.1, 147.6, 138.2, 135.4, 130.9, 128.5, 
128.4, 128.1, 127.7, 127.5, 112.5, 112.1, 56.00, 55.96, 55.5, 51.1, 
41.0, 32.6, 29.7, 28.4, 19.1, 13.9; IR (ATR): ν = 3316, 2961, 1682, 
1621, 1514, 1457, 1352, 1256, 1209, 1130, 1022, 859, 750, 694, 518; 
HRMS (EI, [M]+) for C28H36N2O4
•+ calcd. 464.2670, found 464.2667. 
 
(Z)-N-tert-butyl-2-(1-(4-methoxybenzylidene)-2-oxo-4,5-dihydro-
1H-benzo[d]azepin-3(2H)-yl)-3-phenylpropanamide (103g). Scale: 
0.15 mmol. The material obtained after column chromatography was 
additionally purified by washing with diethyl ether. Yield: 45.6 mg, 
63%. Pale yellow solid; m.p. 210-213°C; 1H NMR (300 MHz, CDCl3): 
δ 7.45-7.33 (m, 1H), 7.33-7.09 (m, 9H), 7.09-6.97 (m, 1H), 6.74 (d, J 
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= 8.1 Hz, 2H), 6.57 (s, 1H), 6.13 (bs, 1H), 5.29-5.10 (m, 1H), 4.19-
3.66 (m, 5H), 3.46-2.80 (m, 4H), 1.12 (s, 9H); 13C NMR (75 MHz, 
CDCl3): δ 172.4, 169.5, 159.4, 137.1, 135.7, 135.5, 135.2, 132.0, 
130.2, 129.9, 129.5, 129.1, 128.6, 128.0, 126.7, 114.0, 57.8, 55.2, 
51.1, 41.7, 33.8, 32.6, 28.2; IR (ATR): ν = 3351, 2962, 1676, 1618, 
1510, 1413, 1250, 1175, 1034, 825, 742, 697, 543; HRMS (EI, [M]+) 
for C31H34N2O3
•+ calcd. 482.2564, found 482.2534. 
 
(Z)-N-cyclohexyl-1-(1-ethylidene-2-oxo-4,5-dihydro-1H-
benzo[d]azepin-3(2H)-yl)cycloheptanecarboxamide (103h). Scale: 
0.15 mmol. Yield: 34.4 mg, 56%. Pale yellow solid; m.p. 152-154°C; 
1H NMR (300 MHz, CDCl3): δ 7.26-7.15 (m, 3H), 7.15-7.07 (m, 1H), 
5.87 (q, J = 7.0 Hz, 1H), 5.62 (bd, J = 7.8 Hz, 1H), 4.04-3.80 (m, 2H), 
3.75-3.50 (m, 1H), 3.31-3.09 (m, 2H), 2.57-2.32 (m, 2H), 2.06-1.98 
(m, 2H), 1.89 (d, J = 7.0 Hz, 3H), 1.84-0.71 (m, 18H); 13C NMR (75 
MHz, CDCl3): δ 174.0, 171.6, 140.8, 135.4, 134.1, 129.98, 129.95, 
129.6, 127.8, 126.8, 69.0, 47.8, 42.1, 35.9, 34.4, 32.5, 30.2, 25.6, 
24.4, 23.9, 15.5; IR (ATR): ν = 3372, 2923, 1679, 1641, 1521, 1405, 
1194, 735, 617; HRMS (EI, [M]+) for C26H36N2O2
•+ calcd. 408.2771, 
found 408.2777. 
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(Z)-2-(benzo[b]thiophen-3-yl)-N-tert-butyl-2-(1-ethylidene-7,8-
dimethoxy-2-oxo-4,5-dihydro-1H-benzo[d]azepin-3(2H)-
yl)acetamide (103i). Scale: 0.2 mmol. Yield: 78 mg, 79%. White 
solid; m.p. 244-246°C; 1H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H), 
7.92-7.82 (m, 1H), 7.72-7.60 (m, 1H), 7.40-7.16 (m, 2H), 6.72 (s, 1H), 
6.52 (s, 1H), 6.23 (bs, 1H), 6.08 (bs, 1H), 5.94 (q, J = 7.0 Hz, 1H), 
3.87 (s, 3H), 3.81-3.60 (m, 5H), 3.06-2.63 (m, 1H), 2.38-2.03 (m, 1H), 
1.97 (d, J = 7.0 Hz, 3H), 1.34 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 
171.6, 168.4, 148.5, 147.2, 139.6, 139.1, 138.3, 130.0, 129.5, 127.9, 
127.3, 126.8, 124.9, 124.5, 122.7, 121.7, 112.4, 112.2, 55.85, 55.79, 
53.5, 51.6, 42.0, 32.7, 28.5, 15.5; IR (ATR): ν = 3357, 2965, 1683, 
1642, 1516, 1458, 1353, 1254, 1024, 845, 767, 573, 494, 431; HRMS 
(EI, [M]+) for C28H32N2O4S
•+ calcd. 492.2077, found 492.2065. 
 
(Z)-3-benzyl-N-cyclohexyl-5-ethylidene-4-oxo-2,3,4,5-tetrahydro-
1H-benzo[d]azepine-2-carboxamide (104a). Scale: 0.2 mmol. Yield: 
76.5 mg, 95%. Pale yellow amorphous solid; 1H NMR (300 MHz, 
CDCl3): δ 7.45-7.28 (m, 5H), 7.25-7.14 (m, 3H), 7.14-7.03 (m, 1H), 
6.01 (q, J = 7.1 Hz, 1H), 5.14 (bd, J = 7.5 Hz, 1H), 4.73 (d, J = 14.6 
Hz, 1H), 4.65 (d, J = 14.6 Hz, 1H), 4.13 (t, J = 4.4 Hz, 1H), 3.52-3.33 
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(m, 2H), 3.26 (dd, J = 4.0, 16.4 Hz, 1H), 2.03 (d, J = 7.1 Hz, 3H), 
1.69-1.37 (m, 5H), 1.29-1.09 (m, 2H), 1.09-0.90 (m, 1H), 0.80-0.50 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 168.6, 168.2, 138.2, 137.2, 
136.4, 133.9, 129.1, 128.7, 128.5, 128.03, 127.95, 127.1, 61.3, 50.7, 
48.4, 33.7, 32.5, 32.4, 25.3, 24.7, 24.6, 16.8; IR (ATR): ν = 3312, 
2926, 2853, 1643, 1537, 1448, 1346, 1221, 729, 699, 453; HRMS (EI, 
[M]+) for C26H30N2O2
•+ calcd. 402.2302, found 402.2321. 
 
(Z)-3-cyclopropyl-N-(4-methoxyphenyl)-4-oxo-5-propylidene-
2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxamide (104b). 
Yield: 90 mg, 77%. Brownish solid; m.p. 161-164°C; 1H NMR (300 
MHz, CDCl3): δ 7.40-7.30 (m, 1H), 7.29-7.10 (m, 6H), 6.80 (d, J = 8.8 
Hz, 2H), 5.85 (t, J = 7.4 Hz, 1H), 4.36 (dd, J = 4.2, 6.0 Hz, 1H), 3.76 
(s, 3H), 3.61 (dd, J = 6.0, 16.6 Hz, 1H), 3.31 (dd, J = 4.2, 16.6 Hz, 
1H), 3.03-2.83 (m, 1H), 2.50-2.28 (m, 1H), 2.26-2.07 (m, 1H), 1.06-
0.86 (m, 5H), 0.80-0.62 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 171.1, 
167.9, 156.6, 143.1, 137.1, 136.2, 133.3, 130.2, 129.0, 128.8, 128.1, 
127.3, 121.6, 114.2, 63.2, 55.5, 34.3, 31.5, 23.8, 13.7, 8.1, 7.9; IR 
(ATR): ν = 3271, 2922, 1684, 1600, 1546, 1506, 1417, 1295, 1223, 
1182, 1033, 835, 744, 714, 532; HRMS (EI, [M]+) for C24H26N2O3
•+ 
calcd. 390.1938, found 390.1952. 
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(Z)-5-benzylidene-N-tert-butyl-4-oxo-3-pentyl-2,3,4,5-tetrahydro-
1H-benzo[d]azepine-2-carboxamide (104c). Scale: 0.3 mmol. Yield: 
111 mg, 88%. Yellow amorphous solid; 1H NMR (300 MHz, CDCl3): δ 
7.64-7.51 (m, 2H), 7.44-7.12 (m, 7H), 6.61 (s, 1H), 5.57 (bs, 1H), 
4.30-4.17 (m, 1H), 3.72-3.55 (m, 2H), 3.54-3.39 (m, 1H), 3.28 (dd, J = 
4.0, 17.0 Hz, 1H), 1.81-1.54 (m, 2H), 1.47-1.27 (m, 4H), 1.00 (s, 9H), 
0.91 (t, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 169.9, 168.0, 
137.4, 136.0, 135.4, 134.4, 129.7, 129.2, 128.8, 128.64, 128.61, 
128.4, 127.2, 62.1, 51.4, 47.3, 33.7, 29.3, 28.1, 22.5, 14.1; IR (ATR): 
ν = 3512, 3320, 2926, 1667, 1599, 1538, 1447, 1363, 1219, 754, 689, 
499; HRMS (EI, [M]+) for C27H34N2O2
•+ calcd. 418.2615, found 
418.2630. 
 
(Z)-3-benzoyl-N-tert-butyl-5-(4-chlorobenzylidene)-4,4-dimethyl-
2,3,4,5-tetrahydro-1H-benzo[d]azepine-2-carboxamide (105). 
Scale: 0.2 mmol. The material obtained after column chromatography 
was additionally purified by washing with diethyl ether. Yield: 49 mg, 
49%. 1H NMR (600 MHz, DMSO-d6, 363 K): δ 7.42 (d, J = 8.3 Hz, 
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2H), 7.39-7.28 (m, 6H), 7.27-7.21 (m, 2H), 7.18-7.13 (m, 1H), 6.90-
6.80 (m, 2H), 6.54 (s, 1H), 6.24 (bs, 1H), 4.45 (dd, J = 6.6, 11.7 Hz, 
1H), 3.44 (dd, J = 11.7, 14.7 Hz, 1H), 3.23 (dd, J = 6.6, 14.7 Hz, 1H), 
1.67 (s, 3H), 1.45 (s, 3H), 1.31 (s, 9H); 13C NMR (150 MHz, DMSO-
d6, 363 K): δ 173.9, 169.7, 152.8, 144.7, 139.6, 137.8, 136.0, 132.2, 
131.1, 130.7, 129.6, 129.2, 128.8, 128.3, 128.2, 127.8, 127.1, 126.8, 
64.3, 62.3, 51.3, 35.0, 31.9, 29.4, 28.9; HRMS (EI, [M]+) for 
C31H33ClN2O2
•+ calcd. 500.2225, found 500.2225. 
 
(Z)-2-(1-benzylidene-4-oxo-4,5-dihydro-1H-benzo[d]azepin-3(2H)-
yl)-N-tert-butylpentanamide (106a). Scale: 0.25 mmol. Yield: 24 mg, 
24%. Yellow amorphous solid; 1H NMR (300 MHz, CDCl3): δ 7.70-
7.59 (m, 1H), 7.48-7.38 (m, 2H), 7.38-7.21 (m, 6H), 6.95 (s, 1H), 5.55 
(bs, 1H), 4.78-4.53 (m, 3H), 3.83 (s, 2H), 1.85-1.63 (m, 2H), 1.48-1.28 
(m, 1H), 1.20-0.99 (m, 10H), 0.79 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 173.9, 169.6, 137.5, 136.4, 136.3, 133.2, 129.5, 
129.1, 128.9, 128.8, 128.4, 128.0, 127.6, 127.3, 57.1, 51.1, 46.1, 
43.4, 30.0, 28.5, 19.2, 13.8; IR (ATR): ν = 3308, 2924, 1668, 1630, 
1541, 1454, 1360, 1221, 750, 696, 562, 501; HRMS (EI, [M]+) for 
C26H32N2O2
•+ calcd. 404.2458, found 404.2475. 
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(Z)-N-tert-butyl-2-(1-(4-chlorobenzylidene)-2,2-dimethyl-4-oxo-
4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(4-
fluorophenyl)acetamide (106b). Scale: 0.15 mmol. The material ob-
tained after column chromatography was additionally purified by re-
versed phase preparative HPLC using gradient pump mode, 
MeCN/H2O with 0.1% HCOOH (30-40-50-60-60-70-70-80-100%, 10 
min intervals) as eluent and a flow rate of 10 mL/min. Yield: 24 mg, 
31%. Yellow amorphous solid; 1H NMR (300 MHz, CDCl3): δ 7.44-
7.22 (m, 6H), 7.18 (d, J = 8.0 Hz, 2H), 6.84-6.68 (m, 2H), 6.68-6.55 
(m, 2H), 6.53 (s, 1H), 6.19 (bs, 1H), 4.71 (s, 1H), 4.15 (d, J = 13.2 Hz, 
1H), 3.54 (d, J = 13.2 Hz, 1H), 1.53 (s, 3H), 1.43 (s, 3H), 1.24 (s, 9H); 
13C NMR (75 MHz, CDCl3): δ 174.0, 169.7, 161.7 (d, J = 246.4 Hz), 
149.7, 142.2, 136.6, 135.5, 133.1, 133.0 (d, J = 3.7 Hz), 129.7, 129.1, 
128.5, 128.4, 128.3, 128.1 (d, J = 4.1 Hz), 127.8, 126.4, 115.2 (d, J = 
21.4 Hz), 65.2, 64.2, 51.1, 43.6, 30.0, 28.5; IR (ATR): ν = 2922, 2852, 
1682, 1641, 1507, 1223, 1155, 1091, 1012, 842, 793, 761, 583, 502, 
457; HRMS (ESI, [M+H]+) for C31H33ClFN2O2
+ calcd. 519.2209, found 
519.2205. 
4.11. Reductive Heck cyclization of propargylamides 102iʹ into 
benzazepines 103i 
Propargylamide 102iʹ (124 mg, 0.2 mmol) was placed into microwave 
vial and dissolved in DMF (2.25 mL) followed by addition of Pd(PPh3)4 
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(7 mg, 0.006 mmol), HCOONa (20.4 mg, 0.3 mmol) and distilled wa-
ter (0.75 mL). The vial was several times evacuated and backfilled 
with argon. When the reaction vial was sealed and irradiated under 
stirring at the set temperature of 90 °C for 15 min utilizing maximum 
power of 100 W. Upon completion of the reaction the vial was cooled 
with a stream of air. The reaction mixture was diluted with EtOAc (40 
mL), washed with water (2×40 mL), dried over Na2SO4 and concen-
trated under reduced pressure. The crude product was subjected to 
column chromatography on silica gel with heptane–EtOAc (30-40%) 
as eluent to give pure 103i. Yield: 90 mg, 91%. 
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Safety aspects 
This section briefly outlines some guidelines and advices for the safe 
handling of materials and chemicals, when dealing with the protocols 
described in this thesis.  
Before set up any experiment, it is highly recommended to go through 
the MSDS for all involved substances. In the current work, we have 
utilized a number of commercially available amines, aldehydes, or-
ganic acids, and isocyanides most of which are included in the KU 
Leuven Database of Hazardous Products that is another main source 
of information for the risk assessments. 
Isocyanides are particularly toxic (by inhalation and in contact with 
scin). All syringes and laboratory glass exposed to isocyanides 
should be thoroughly washed in the fumehood and the generated 
wast should be appropriately treated and discarded. Volatile isocya-
nides have a very bad irritating smell. 
It is also worth emphasizing that in case of inappropriate handling 
some commonly used solvents and materials may also possess un-
derestimated danger to health. For example, chronic exposure to 
DCM is associated with a risk of cancer hazard. Long-term exposure 
(10 years or more) even to relatively low concentrations of silica dust 
may result in developing chronic silicosis.77 
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